WO2013154733A1 - Protein restriction for disease prevention and treatment - Google Patents

Protein restriction for disease prevention and treatment Download PDF

Info

Publication number
WO2013154733A1
WO2013154733A1 PCT/US2013/031061 US2013031061W WO2013154733A1 WO 2013154733 A1 WO2013154733 A1 WO 2013154733A1 US 2013031061 W US2013031061 W US 2013031061W WO 2013154733 A1 WO2013154733 A1 WO 2013154733A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
person
intake
period
nutrient material
Prior art date
Application number
PCT/US2013/031061
Other languages
French (fr)
Inventor
James W. Hill
Original Assignee
Hill James W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/604,535 external-priority patent/US9578892B2/en
Application filed by Hill James W filed Critical Hill James W
Publication of WO2013154733A1 publication Critical patent/WO2013154733A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula

Definitions

  • the subject technology relates generally to human nutrition, health, and disease prevention and treatment.
  • Macroautophagy (sometimes referred to herein as “autophagy”) is a cellular "self-eating" process conserved among eukaryotic cells and involving digestion of cytoplasmic components via lysosomes. During starvation, stimulation of autophagy can provide cells with macronutrients to maintain metabolism and energy levels to survive.
  • a method of preventing and/or treating disease comprising:
  • the meals comprise (a) lower-protein meals configured to be administered to the person during the lower-protein period and (b) higher- protein meals configured to be administered to the person during the higher-protein period.
  • a system for preventing and/or treating disease comprising:
  • a person eat the food according to the following: (i) during a lower-protein period of at least two days, the person eats a lower-protein portion of the food, such that the person's dietary intake of protein is restricted to less than 40 grams per day; and
  • each of the lower-protein portion and the higher-protein portion comprise a plurality of meals configured to be provided to the person.
  • a system for preventing and/or treating disease comprising:
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • autoimmune disorder comprises at least one of thyroiditis, hyperthyroidism, or hypothyroidism.
  • autoimmune disorder comprises a Human Leukocyte Antigen (HLA) B27 associated disease.
  • HLA Human Leukocyte Antigen
  • the autoimmune disorder comprises at least one of rheumatoid arthritis, ankylosing spondylitis, an anterior uveitis, or psoriatic arthritis.
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • a method of slowing a rate of accumulation of mitochondrial damage in a mammal comprising:
  • a system for preventing and/or treating disease comprising:
  • nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising (a) at least one of lipid or carbohydrate and (b) at least one higher-protein portion and at least one lower-protein portion;
  • the material is configured to be administered to the person in the following sequence:
  • the person receives the at least one lower-protein portion such that the person's bodily intake of protein is restricted to less than 0.4 mg/kg of the person's bodyweight per day; and (ii) during a higher-protein period that is after the lower-protein period and is at least one day, the person receives the at least one higher-protein portion such that the person's bodily intake of protein exceeds 0.6 mg/kg of the person's bodyweight per day.
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • the atrial dysrhythmia comprises at least one of atrial fibrillation or atrial flutter.
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • ventricular dysrhythmia comprises at least one of ventricular fibrillation or ventricular tachycardia.
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • ventricular dysrhythmia comprises at least one of ventricular fibrillation or ventricular tachycardia.
  • a method for providing nutrients to a person to maintain or enhance health comprising:
  • nutrient material administrable to at least one of the person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
  • carbohydrate be, or may be, administered to the person such that the person's bodily intake of carbohydrate is at least 40 grams per day during the lower- protein period;
  • a method for providing nutrients to a person to maintain or enhance health comprising:
  • nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
  • nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
  • carbohydrate be, or may be, administered to the person such that the person's bodily intake of carbohydrate is at least 40 grams per day during the lower- protein period;
  • a method for providing nutrients to a person to maintain or enhance health comprising:
  • nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
  • carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 40 grams per day, and is not limited to 150 grams per day, during the lower-protein period; and instructing that, during a higher-protein time period that is after the lower-protein period and is at least 24 hours, the person receives a higher bodily intake of protein than the person received during the lower-protein period.
  • a method for providing nutrients to a person to maintain or enhance health comprising: (a) providing nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
  • a method of reducing at least one of a likelihood or a severity of disease comprising: (i) to a person selected for having at least one of osteoporosis, osteopenia, or a significant risk of osteoporosis, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 30 grams per day during a lower- protein period of at least one day;
  • a method of reducing at least one of a likelihood or a severity of disease comprising:
  • nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
  • the nutrient material comprises at least one of an omega-3 or an omega-6 fatty acid.
  • the first portion is administered to the person such that person's bodily intake of all protein is restricted to less than 30 grams per day during a lower-protein time period of at least 48 hours;
  • nutrition is administered to the person such that the person's bodily intake of carbohydrate constitutes at least 40 percent of the person's bodily intake of energy during the lower-protein period;
  • the second portion is administered to the person during a higher-protein time period that is after the lower-protein period and is at least 24 hours and no more than 14 days, such that the person receives a higher daily bodily intake of protein than the person received during the lower-protein period.
  • a phrase such as "an aspect” does not imply that such aspect is essential to the subject technology or that such aspect applies to all configurations of the subject technology.
  • a disclosure relating to an aspect may apply to all configurations, or one or more configurations.
  • An aspect may provide one or more examples of the disclosure.
  • a phrase such as “an aspect” may refer to one or more aspects and vice versa.
  • a phrase such as “an embodiment” does not imply that such embodiment is essential to the subject technology or that such embodiment applies to all configurations of the subject technology.
  • a disclosure relating to an embodiment may apply to all embodiments, or one or more embodiments.
  • An embodiment may provide one or more examples of the disclosure.
  • a phrase such "an embodiment” may refer to one or more embodiments and vice versa.
  • a phrase such as "a configuration” does not imply that such configuration is essential to the subject technology or that such configuration applies to all configurations of the subject technology.
  • a disclosure relating to a configuration may apply to all configurations, or one or more configurations.
  • a configuration may provide one or more examples of the disclosure.
  • a phrase such as "a configuration” may refer to one or more configurations and vice versa.
  • Autophagy is a homeostatic "self-eating" process that has been conserved among eukaryotic cells and which involves the digestion of cytoplasmic components via the lysosomal pathway. Under normal conditions, it allows cells to break down long-lived proteins, thus complementing the action of the proteasome, which deals chiefly with short-lived proteins.
  • stimulation of autophagy is important to provide cells exposed to nutrient deprivation with amino acids, glucose, and fatty acids to maintain metabolism and ATP levels compatible with cell survival.
  • Stimulation of autophagy plays a critical role in counteracting nutrient deprivation following birth in newborn mice.
  • autophagy helps the cell to get rid of damaged organelles, such as mitochondria and toxic aggregation-prone proteins.
  • the functions of autophagy are not limited to these aspects, but extend beyond, as shown by the discovery of its role in the innate and adaptive immune responses.
  • Autophagy malfunction contributes to the pathogenesis of a variety of diseases, including cancer, neurodegenerative and cardiovascular disorders, and infectious diseases.
  • Another important aspect of autophagy in mammalian cells that remains to be unraveled is the role of autophagy in cell death, which has been the topic of several recent reviews.
  • phagophore part of the cytoplasm containing long-lived proteins or organelles is surrounded by a cisternal membrane, designated the phagophore by Seglen.
  • isolation membrane is also used as a synonym of phagophore.
  • the phagophore then closes to form a double-membraned vacuole, known as the autophagosome.
  • Autophagosomes use dynein motors to move along microtubules towards the microtubule organizing center, where they fuse with lysosomes to form autolysosomes. However, most of the autophagosomes receive input from the endocytic compartments before they fuse with lysosomes.
  • ATG AuTophaGy-related genes identified in yeast by genetic screens have mammalian counterparts, and 18 different Atg proteins are known to be recruited to the isolation membrane, where they are involved in autophagosome formation.
  • ER endoplasmic reticulum
  • Electron tomography analyses demonstrate a direct connection between the ER and the phagophore.
  • Autophagy refers to the process by which lysosomes degrade intracellular constituents, including both organelles and soluble proteins. This process is traditionally regarded as a cellular response to stress typically related to nutrient deprivation, toxin exposure, infection, or oxidative stress.
  • autophagy In contrast to the ubiquitin-proteasome pathway which degrades mostly shortlived proteins, autophagy is mainly involved in breaking down proteins with long-half lives and damaged organelles. Some basic form of this machinery is highly conserved from yeast to mammals. Depending on how lysosomes receive the cargo, autophagy can be further classified into three types, namely macroautophagy, microautophagy, and chaperone-mediated autophagy (CM A).
  • CM A chaperone-mediated autophagy
  • Macroautophagy involves multiple steps beginning with induction and ending with the release of the degraded products to the cytosol. It is characterized by the sequestration of cytosolic components in an autophagic vacuole or autophagosome, which fuses with lysosomal membrane to deliver its contents for degradation.
  • This double-membrane vacuole is the morphological hallmark of autophagy.
  • the process is highly inducible in response to stress signals and regulated at various junctures by a large number of autophagy-related (ATG) genes, which involves controlling the activity of mTOR (mammalian target of rapamycin), a suppressor of macroautophagy.
  • ATG autophagy-related
  • Microautophagy is less well studied than macroautophagy. Unlike macroautophagy, microautophagy does not involve the formation of double-membrane vacuoles.
  • microautophagy is the invagination or exvagination of lysosomal membrane to sequester cytosolic components.
  • Mitophagy is a term describing the selective sequestration and removal of mitochondria by either macro- or microautophagy.
  • CMA does not involve membrane vacuoles. Rather, it is regulated by direct protein interaction. Two key regulators, chaperone protein heat-shock cognate 70 (Hsc70) and lysosomal membrane receptor Lamp2A, control the CMA process.
  • Hsc70 chaperone protein heat-shock cognate 70
  • Lamp2A lysosomal membrane receptor Lamp2A
  • Hsc70 in a complex with other co-chaperone proteins, binds to cytosolic proteins containing a pentapeptide targeting motif KFERQ and delivers substrate proteins to the surface of lysosomes. Binding of this chaperone-substrate complex to Lamp2A leads to the translocation of substrates cross the lysosomal membrane. Both the level and availability of Lamp2A are regulated by stress signals, making Lamp2A one of the major modes by which CMA activity is controlled.
  • Protein restriction can affect disease states and the rate of aging in an organism, such as a human, in a variety of ways including, but not limited to, (a) reducing the rate of production of free radicals (as reactive oxygen species) in mitochondria, leading to reduced oxidation and mutation rates in mitochondrial DNA and RNA; (b) decreasing the degree of membrane fatty acid unsaturation in cells, including in the mitochondrial inner membrane, lowering the susceptibility of membranes to oxidative damage; and (c) increasing autophagy, to repair or replace cellular structures, such as damaged organelles and proteins.
  • a physician, other health care professional, or subject person can adjust the amount and duration of restriction and/or nonrestriction of protein administered to the person.
  • those of skill in the art can, without difficulty or undue experimentation, to adjust or titrate nutritional parameters, such as daily protein intake and the number of days of protein restriction, to optimize the attainment in the person of such endpoints as disease prevention or amelioration. This is accomplished by, for example, observing the effect of any significant change in a pattern of the person's protein intake over weeks to months.
  • the degree of consumption or restriction of a person's protein (or other macronutrient) intake may be specified either in absolute or relative terms, such as by, e.g., daily or weekly total intake, or in mass or weight of protein per mass or weight of a person or her fat mass or her lean mass (e.g., mg of protein (or other macronutrient) per kg of the person's bodyweight). All claimed methods, compositions, and systems are intended to encompass any such type of specification. Thus, all methods and systems disclosed as one of the following two options (relative or absolute macronutrient intake) also includes the other:
  • First exemplary option (i) during a lower-protein period, the person receives a lower-protein portion such that the person's bodily intake of protein is restricted to less than 0.4 mg/kg of the person's bodyweight per day; and (ii) during a higher-protein period that is after the lower-protein period, the person receives a higher-protein portion such that the person's bodily intake of protein exceeds 0.6 mg/kg of the person's bodyweight per day.
  • Second exemplary option (i) administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 40 grams per day during a lower- protein period of at least one day; and (ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 40 grams per day during a higher-protein period.
  • Some aspects of the subject technology include a method for providing nutrients to a person to maintain or enhance health, comprising: providing nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate; wherein all of any protein in the material constitutes less than 5 percent of a caloric content of the material; instructing that the material be administered to the person such that the person's bodily intake of at least one of protein, peptides, or amino acids is restricted to less than 30 grams per day during a lower-protein time period of at least 48 hours; instructing that carbohydrate be, or may be, administered to the person such that the person's bodily intake of carbohydrate is at least 40 grams per day during the lower-protein period; and instructing that, during a higher-protein time period that is after the lower-protein period and is at least 24 hours, the person receives a higher bodily intake of protein than the person received during the lower-protein period, such that the average daily bodily intake of
  • the lower-protein period can be at least 24 hours, at least 36 hours, at least 72 hours, at least 96 hours, at least 120 hours, or similar minimum duration.
  • the inventor has found that autophagy in at least hepatocytes and neurons is unexpectedly stimulated to a beneficial degree during periods of dietary protein restriction despite a concomitant dietary carbohydrate intake of, e.g., at least 40 grams per day or at least 60 percent of total caloric intake, and despite its attendant elevation of insulin. Elevated insulin has been previously thought to prevent, generally uniformly, autophagy or to prevent substantial increases in autophagy.
  • the lower-protein time period is at least 36 hours.
  • LRRK2 mutants have been recently found to induce the increase or accumulation of autophagic vacuoles. Loss of PINK1 function has been proposed to affect autophagy.
  • Intracellular protein misfolding and aggregation are features of many late- onset neurodegenerative diseases called proteinopathies. These include Alzheimer's disease, Parkinson's disease, tauopathies, and polyglutamine expansion diseases [e.g., Huntington's disease and various spinocerebellar ataxias (SCAs), like SCA3].
  • proteinopathies include Alzheimer's disease, Parkinson's disease, tauopathies, and polyglutamine expansion diseases [e.g., Huntington's disease and various spinocerebellar ataxias (SCAs), like SCA3].
  • SCAs spinocerebellar ataxias
  • proteasome and autophagy-lysosomal pathways are the major routes for mutant huntingtin fragment clearance. While the narrow proteasome barrel precludes entry of oligomers and aggregates of mutant huntingtin (or other aggregate-prone intracellular proteins), such substrates can be degraded by macroautophagy.
  • Rapamycin reduces levels of soluble and aggregated huntingtin and attenuates its toxicity in cells and in transgenic Drosophila and mouse models.
  • the range of intracellular proteinopathy substrates that are cleared by autophagy includes other targets, including proteins mutated in certain SCAs, forms of synuclein mutated in familial forms of Parkinson's disease, and tau mutants that cause frontotemporal dementia/tauopathy.
  • This section discusses the therapeutic potential of autophagy upregulation for various proteinopathies, and describes how this strategy may act both by removing the primary toxin (the misfolded/aggregate-prone protein) and by reducing susceptibility to apoptotic insults.
  • Intracellular protein misfolding and aggregation are features of many late- onset neurodegenerative diseases called proteinopathies. These include Alzheimer's disease, Parkinson's disease, tauopathies, and various diseases caused by abnormally expanded tracts of the amino acid glutamine, like Huntington's disease (HD).
  • HD is an autosomal-dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion, which results in an abnormally long polyglutamine (polyQ) tract in the N-terminus of huntingtin.
  • polyQ polyglutamine
  • Asymptomatic individuals have 35 or fewer CAG repeats, while HD is caused by expansions of 36 or more repeats.
  • HD belongs to a group of human neurodegenerative disorders caused by CAG repeat/polyQ expansions, which includes spinocerebellar ataxias (SCAs) type 1, 2, 3, 6, 7, and 17, spinobulbar muscular dystrophy (SBMA), and dentatorubral pallidoluysian atrophy (DRPLA).
  • SCAs spinocerebellar ataxias
  • SBMA spinobulbar muscular dystrophy
  • DRPLA dentatorubral pallidoluysian atrophy
  • Autophagy is a bulk degradation process that involves the sequestration of portions of cytoplasm by a double-membrane autophagosome, followed by digestion of the sequestered material when the autophagosome fuses with a lysosome full of hydrolytic enzymes.
  • the immunosuppressant rapamycin stimulates autophagy and aggregate digestion by inhibiting the evolutionarily conserved protein kinase TOR (target of rapamycin).
  • TOR acts as a brake on autophagy; thus, when it is inhibited with rapamycin, autophagy is turned on.
  • TOR does not control autophagy alone— it is also an activator of ribosome biogenesis and other pathways involved in cell growth. This causes undesired side effects, such as immunosuppression, during long-term administration of rapamycin, and therefore alternative inducers of autophagy are desired.
  • Dietary protein restriction can achieve many of the same effects as calorie restriction, though protein restriction is generally better tolerated by humans than severe calorie restriction. In other words, the subject technology can be implemented effectively without restricting calories.
  • Example for treatment of neurodegeneration As proof of principle for the subject technology, an experimental study using dietary protein restriction cycles was performed and resulted in reduced IGF-1 and phosphorylated tau, and improve behavioral performance, in an Alzheimer's disease (AD) mouse model. Reduced levels of growth hormone and IGF-1, which mediate some of the protective effects of caloric restriction (CR), can also extend longevity and protect against age-related diseases in rodents and humans.
  • PRC periodic protein restriction cycles
  • PRC periodic protein restriction cycles with supplementation of non-essential amino acids in mice already displaying significant cognitive impairment and AD-like pathology reduced circulating IGF-1 levels by 30-70% and caused an 8- fold increase in IGFBP-1.
  • the protein cycles lasted four months and consisted of alternating weeks of a normal diet and a protein-restricted (PR) diet.
  • the PR diet lacked nine essential amino acids (EAA) - that is, amino acids the body cannot make: isoleucine, leucine, lysine, methionine, phenyalanine, threonine, tryptophan, valine, and arginine. Both the treatment and normal diets contained about 60% carbohydrate
  • One approach to treating and/or preventing any disease according to the subject technology is to restrict protein markedly for a first period, then to resume normal protein feeding during a second period. This accomplishes two goals: (1) stimulating autophagy during the first period, thereby helping clear cells of debris; and (2) preventing protein malnutrition during the second period.
  • protein intake may be restricted for up to one day, followed by a period of differing protein intake.
  • the subject technology also includes restricting protein for longer periods, for at least two days, for example, followed by a period of normal to high protein intake.
  • This longer duration of autophagy better assists in clearing cells of abnormal proteins (e.g., oxidized, glycated, and fructated proteins) and abnormal organelles, such as mitochondria and lysosomes. This can assist in preventing and treating diseases caused or exacerbated by an accumulation of cellular debris, such as in the heart, pancreas, liver, brain, and skeletal muscles, leading to organ dysfunction.
  • Protein restriction can be used according to the subject technology to enhance autophagy and, in some cases, induce cell death, through apoptosis or otherwise, in patients with neoplasms that either benign (e.g., meningioma) or malignant (e.g., astrocytoma).
  • neoplasms that either benign (e.g., meningioma) or malignant (e.g., astrocytoma).
  • the drug minocycline induces nonapoptotic cell death, which is associated with the presence of autophagic vacuoles in the cytoplasm.
  • Minocycline induces autophagy, as confirmed by acridine orange, monodansylcadaverine (MDC) stainings of vesicle formation, and the conversion of microtubule-associated proteins light chain 3 (LC3-I) to LC3-II.
  • MDC monodansylcadaverine
  • LC3-I microtubule-associated proteins light chain 3
  • Pretreatment with autophagy inhibitor 3-methyladenine (3-MA) suppresses induction of acidic vesicular organelles and the accumulation of LC3-II to the autophagosome membrane in glioma cells treated with minocycline.
  • 3-MA 3-methyladenine
  • minocycline induces cell death via apparent activation of caspase-3.
  • Minocycline effectively inhibits tumor growth and induces autophagy in the xenograft tumor model of C6 glioma cells.
  • minocycline appears to kill glioma cells by inducing autophagic cell death.
  • stimulation of autophagy by restriction of protein intake according to principles of the subject technology is a promising therapeutic intervention for malignant gliomas and other cancers.
  • an "autoimmune disorder” is any disorder known or suspected by medical researchers to be related to self-targeting of a mammalian (e.g., human) immune system, such that inflammation results.
  • a mammalian (e.g., human) immune system such that inflammation results.
  • Each of the following disorders is known or suspected to be autoimmune in nature and can, in certain cases, be treated, prevented, and/or have its severity or progression lessened in a person by restriction of the person's bodily intake of protein according to methods and systems of the subject technology.
  • i Crohns Disease one of two types of idiopathic
  • IBD inflammatory bowel disease
  • LAD Linear IgA disease
  • IBD inflammatory bowel disease
  • Atg7 In both genetic and dietary models of obesity, one can observe a marked downregulation of autophagy, particularly in Atg7 expression levels in liver. Suppression of Atg7 both in vitro and in vivo results in defective insulin signaling and elevated endoplasmic reticulum (ER) stress. In contrast, restoration of Atg7 expression in liver results in dampened ER stress, enhanced hepatic insulin action, and systemic glucose tolerance in obese mice. Beneficial Atg7 restoration in obese mice can be prevented by blocking a downstream autophagy mediator, Atg5, supporting the concept of AtgVs dependence on autophagy for regulating insulin action.
  • Atg5 downstream autophagy mediator
  • autophagy is an important regulator of organelle function and insulin signaling, and loss of autophagy contributes strongly to the defective insulin action of obesity, which in turn leads to many known sequelae and is associated with, for example, hypertension, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, certain cancers, cholelithiasis, depression, coronary artery disease, peripheral vascular disease, type 2 diabetes, Alzheimer's disease, and other dementia syndromes.
  • Type 2 diabetes mellitus is characterized by insulin resistance and failure of pancreatic beta cells producing insulin.
  • Mitochondrial dysfunction plays a role in both processes of diabetes.
  • Autophagy which can be upregulated by restriction of dietary energy and/or protein, maintains cellular homeostasis through degradation and recycling of organelles such as mitochondria.
  • As dysfunctional mitochondria are the main organelles removed by autophagy one can observe the role of autophagy in diabetes using mice with beta cell-specific deletion of, for example, the Atg7 gene. Atg7-mutant mice show reduction in beta cell mass and pancreatic insulin content.
  • Electron microscopy shows swollen mitochondria and other ultrastructural changes in autophagy-deficient beta cells. Insulin secretory function ex vivo is also impaired.
  • Atg7-mutant mice show hypoinsulinemia and hyperglycemia.
  • Autophagy appears necessary to maintain structure, mass, and function of beta cells. Besides its effect on beta cells, autophagy affects insulin sensitivity because mitochondrial dysfunction is implicated in insulin resistance and autophagy is involved in the maintenance of organelles, including mitochondria. Furthermore, since aging is associated with impaired glucose tolerance, decline of autophagic activity appears to be involved in age-associated reduction of glucose tolerance.
  • Autophagy acts an immune mechanism.
  • One of the model systems showing how autophagy and more traditional immunity systems cooperate in defense against intracellular pathogens is macrophage infection with Mycobacterium tuberculosis.
  • M. tuberculosis is a significant human pathogen that latently infects billions of people and causes active disease in millions of patients worldwide.
  • the ability of the tubercle bacillus to persist in human populations rests upon its macrophage parasitism.
  • Autophagy can act as a cell-autonomous innate immunity mechanism capable of eliminating intracellular bacteria, e.g., M. tuberculosis.
  • Embodiments of the subject technology recognize that: (1) autophagy functions as an innate defense mechanism against intracellular microbes; (2) autophagy is under the control of pattern recognition receptors (PRR) such as Toll-like receptors (TLR), and it acts as an immunological output effector of PRR and TLR signaling; (3) autophagy is one of the effector functions associated with the immunity-regulated GTPases, which are molecules involved in cell- autonomous defense; (4) autophagy is an immune effector of Thl/Th2 T cell response polarization— autophagy is activated by Thl cytokines (acting in defense against intracellular pathogens) and is inhibited by Th2 cytokines (making cells accessible to intracellular pathogens). As an ancient innate immunity defense, autophagy became integrated over the course of evolution with other immune mechanisms of increasing complexity.
  • PRR pattern recognition receptors
  • TLR Toll-like receptors
  • Age-related macular degeneration is the major cause of blindness in the elderly, over 1.75 million people having reduced vision due to AMD in the United States. AMD is broadly divided into two forms, dry and wet, that account for about 85% and 15% of cases, respectively.
  • An early sign of AMD is the appearance of drusen, which are extracellular deposits that accumulate on Bruch' s membrane, and are thought to derive from the overlying retinal pigment epithelium (RPE).
  • RPE retinal pigment epithelium
  • Scientists have proposed that increased autophagy and the release of intracellular proteins via exosomes by the aged RPE may contribute to the formation of drusen. Furthermore, a decline in autophagic efficiency in the RPE is associated with the later pathological stages of AMD and cellular dysfunction.
  • Primary open angle glaucoma is an optic neuropathy characterized by the elevation of intraocular pressure, which causes retinal ischemia and neuronal death.
  • I/R ischemia/reperfusion
  • 3-methyladenine partially prevents death of neurons and reduces apoptotic markers, 24 h post-lesion.
  • the number of neurons in the GCL decreases significantly following I/R; this decrease is partially prevented by 3-methyladenine, which potently inhibits maturation of autophagosomes.
  • Treatment also prevents the increase in glial fibrillary acid protein immunoreactivity elicited by I/R. Therefore, stimulating autophagy provides treatment for glaucoma and retinal ischemia.
  • Osteoporosis, osteopenia, and other disorders of bone density and/or mineralization can, in certain cases, be treated, prevented, and/or have its severity or progression lessened in a person by episodic restriction of the person' s bodily intake of protein according to methods and systems of the subject technology.
  • Chronic kidney disease can, in certain cases, be treated, prevented, and/or have its severity or progression lessened in a person by episodic restriction of the person's bodily intake of protein according to methods and systems of the subject technology.
  • Male pattern baldness, or alopecia androgenica is marked typically by higher levels of 5-alpha-reductase, lower levels of total testosterone, higher levels of unbound/free testosterone, and higher levels of total free androgens including DHT.
  • 5-alpha-reductase is responsible for converting free testosterone into DHT.
  • the enzymes are present predominantly in the scalp and prostate.
  • Levels of 5-alpha-reductase are one factor in determining levels of DHT in the scalp.
  • Drugs which interfere with 5-alpha-reductase such as finasteride, which inhibits the predominant type 2 isoform have been approved by the FDA as treatments for hair loss.
  • Sex hormone-binding globulin which is responsible for binding testosterone and preventing its bioavailability and conversion to DHT, is typically lower in individuals with high DHT. SHBG is downregulated by insulin.
  • IGF-1 Insulin Growth Factor-1
  • glutamine is transported into cells via the SLC1A5 glutamine transporter and is subsequently used to import leucine via the SLC7A5-SLC3A2 complex.
  • Intracellular leucine activates mTORCl Rag GTPases or a second pathway. Basal autophagy is maintained under these conditions by the activity of Beclin-1, which is inhibited by anti-apoptotic Bcl-2 and Bel -XL. Bcl-2 and Bcl-XL also function to maintain viability by antagonizing Bax/Bak-dependent mitochondrial apoptosis.
  • EAA essential amino acids
  • mitochondrial reactive oxygen species mitROS
  • mtDNA mitochondrial DNA
  • Enrichment of omega-6 (co-6) polyunsaturated fatty acids (PUFAs) promotes starvation resistance and extends Caenorhabditis elegans life span.
  • C. elegans Upon fasting, C. elegans induces expression of a lipase, leading to an enrichment of co-6 PUFAs.
  • Supplementing C. elegans culture media with these co-6 PUFAs increases their resistance to starvation and extends their life span in conditions of food abundance.
  • Supplementation of C. elegans or human epithelial cells with these co-6 PUFAs activates autophagy, a cell recycling mechanism that promotes starvation survival and slows aging. Inactivation of C.
  • elegans autophagy components reverses the increase in life span conferred by supplementing the C. elegans diet with these fasting-enriched co-6 PUFAs. Dietary supplementation with co-3/6 PUFAs (fish oils) is beneficial due, at least in part, to activation of autophagy.
  • DHA docosahexaenoic acid
  • EPA eicosapentaenoic acid
  • Dietary DHA and EPA can be converted to their ethanolamide derivatives, docosahexaenoyl ethanolamine (DHEA), and eicosapentaenoyl ethanolamine (EPEA), respectively.
  • DHEA and EPEA reduce cell viability in MCF-7 breast cancer cells whereas they do not elicit effects in MCF-IOA non-tumorigenic breast epithelial cells.
  • DHA and EPA are ligands of Peroxisome Proliferator-Activated Receptor gamma (PPARy).
  • PPARy Peroxisome Proliferator-Activated Receptor gamma
  • MCF-7 cells both compounds enhanced PPARy expression, stimulated a PPAR response element-dependent transcription as confirmed by the increased expression of its target gene PTEN, resulting in the inhibition of AKT-mTOR pathways.
  • DHEA and EPEA treatment induce phosphorylation of Bcl- 2, promoting its dissociation from beclin-1 which results in autophagy induction.
  • the two omega-3 ethanolamides exert anti-proliferative effects by inducing autophagy in breast cancer cells highlighting their potential use as breast cancer preventive and/or therapeutic agents. Supplementation of omega-3 and/or omega-6 fatty acids is effective for amelioration of diseases according to principles of the subject disclosure.
  • a period of at least a particular time (e.g., “a period of at least one day”) refers to time period having of a duration of at least as long as that time (e.g., a period lasting one day or more in duration).
  • a phrase such as "instructing that the material be administered to X" can refer either to self-administration by X, or to administration to X by another person or agent, such as a health care worker or a machine, such as a robot.
  • all protein and all of any protein have at least their ordinary meaning and are further defined to include all proteins, peptides, polypeptides, and amino acids, free or otherwise, in a particular material, food, meal, other circumstance, or time period of consumption, ingestion, or administration.
  • meal is a broad term that encompasses its ordinary meaning and can refer to a food and/or drink (or beverage) portion of any size, such as a snack or food "treat,” whether frozen, chilled, hot, cookable, microwaveable, reheatable, or raw. Such a meal may be ingested enterally, such as orally or by gastrostomy.
  • the phrase "at least one of preceding a series of items, with the term “and” or “or” to separate any of the items, modifies the list as a whole, rather than each member of the list (i.e., each item).
  • the phrase "at least one of can include, but does not require, selection of at least one of each item in the series. Rather, the phrase allows a meaning that includes at least one of any one of the items, and/or at least one of any combination of the items, and/or at least one of each of the items.
  • the phrase “at least one of A, B, and C” includes at least one of only A, of only B, of only C, of any combination of A, B, and C; and/or of each of A, B, and C.
  • top should be understood as referring to an arbitrary frame of reference, rather than to the ordinary gravitational frame of reference.
  • a top surface, a bottom surface, a front surface, and a rear surface may extend upwardly, downwardly, diagonally, or horizontally in a gravitational frame of reference.

Abstract

Nutrient material can be used for preventing or treating diseases such as neurodegeneration. Protein in a first portion of the material constitutes no more than 5 percent, and protein in a second portion constitutes at least 10 percent, of the material's caloric content. Use of the material can be such that: (a) the first portion is administered such that person's intake of protein is restricted to less than 30 grams per day during a lower-protein period of at least 48 hours; (b) nutrition is administered such that the person's intake of carbohydrate constitutes at least 40 percent of the person's energy intake during the lower-protein period; and (c) the second portion is administered during a higher-protein period, after the lower-protein period, that between 24 hours and 14 days long, such that the person receives a higher daily intake of protein than the person received during the lower-protein period.

Description

Protein Restriction for Disease Prevention and Treatment
Related Applications
[0001] This application claims the priority benefit of U.S. Patent Application 13/604,535, filed September 5, 2012; U.S. Provisional Application No. 61/534,344, filed September 13, 2011 ; U.S. Provisional Application No. 61/621,959, filed April 9, 2012; U.S. Provisional Application No. 61/671,591, filed July 13, 2012; and U.S. Provisional Application No. 61/679,782, filed August 6, 2012; each of the foregoing applications entitled "Protein Restriction for Disease Prevention and Treatment," and the entirety of each of which is incorporated herein by reference.
Field
[0002] The subject technology relates generally to human nutrition, health, and disease prevention and treatment.
Background
[0003] Macroautophagy (sometimes referred to herein as "autophagy") is a cellular "self-eating" process conserved among eukaryotic cells and involving digestion of cytoplasmic components via lysosomes. During starvation, stimulation of autophagy can provide cells with macronutrients to maintain metabolism and energy levels to survive.
Summary
[0004] The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples and do not limit the subject technology. It is noted that any of the dependent clauses may be combined in any combination and placed into a respective independent clause or into other of the independent clauses. Other clauses can be presented in a similar manner.
1. A method of preventing and/or treating disease, comprising:
(i) administering nutrients to a person such that the person's dietary intake of protein is restricted to less than 40 grams per day during a lower-protein period of at least two days; (ii) after the lower-protein period, administering nutrients to the person such that the person's dietary intake of protein exceeds 40 grams per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
2. The method of clause 1, wherein the administering comprises providing to the person a plurality of meals.
3. The method of clause 1, wherein the administering comprises providing to the person a plurality of meals, at least two of which are configured to be ingested by the person per day.
4. The method of clause 1 , wherein the meals are substantially liquid.
5. The method of clause 1, wherein the meals comprise (a) lower-protein meals configured to be administered to the person during the lower-protein period and (b) higher- protein meals configured to be administered to the person during the higher-protein period.
6. The method of clause 1, further comprising administering carbohydrate in a sufficient amount to prevent a negative nitrogen balance exceeding 5 grams of nitrogen per day.
7. The method of clause 1, further comprising administering carbohydrate in a sufficient amount to prevent a negative nitrogen balance exceeding 10 grams of nitrogen per day.
8. The method of clause 1, wherein the person's dietary intake of protein is restricted to less than 0.6 grams/kg body weight/day during the lower-protein period.
9. The method of clause 1, wherein the person's dietary intake of protein is restricted to less than 0.4 grams/kg body weight/day during the lower-protein period.
10. The method of clause 1, wherein the person's dietary intake of protein is restricted to less than 0.3 grams/kg body weight/day during the lower-protein period.
11. The method of clause 1, wherein the person's dietary intake of protein is restricted to less than 0.2 grams/kg body weight/day during the lower-protein period.
12. The method of clause 1, wherein the person's dietary intake of protein is restricted to less than 0.1 grams/kg body weight/day during the lower-protein period.
13. The method of clause 1, wherein the person's dietary intake of protein is restricted to less than 30 grams per day during the lower-protein period. 14. The method of clause 1, wherein the person's dietary intake of protein is restricted to less than 20 grams per day during the lower-protein period.
15. The method of clause 1, wherein the person's dietary intake of protein is restricted to less than 10 grams per day during the lower-protein period.
16. The method of clause 1, wherein the person's dietary intake of protein is restricted to less than 5 grams per day during the lower-protein period.
17. The method of clause 1, wherein the person's dietary intake of protein is restricted to about zero grams per day during the lower-protein period.
18. The method of clause 1, wherein the lower-protein period is at least 3 days.
19. The method of clause 1, wherein the lower-protein period is at least 4 days.
20. The method of clause 1, wherein the lower-protein period is at least 5 days.
21. The method of clause 1, wherein the lower-protein period is at least 6 days.
22. The method of clause 1, wherein the lower-protein period is at least 7 days.
23. The method of clause 1, wherein the lower-protein period is at least 8 days.
24. The method of clause 1, wherein the lower-protein period is at least 9 days.
25. The method of clause 1, wherein the lower-protein period is at least 10 days.
26. The method of clause 1, wherein the lower-protein period is at least 14 days.
27. The method of clause 1, wherein the lower-protein period is at least 21 days.
28. The method of clause 1, wherein the person's dietary intake of protein exceeds 0.8 grams/kg body weight/day during the higher-protein period.
29. The method of clause 1, wherein the person's dietary intake of protein exceeds 1.0 grams/kg body weight/day during the higher-protein period.
30. The method of clause 1, wherein the person's dietary intake of protein exceeds 1.2 grams/kg body weight/day during the higher-protein period.
31. The method of clause 1, wherein the person's dietary intake of protein exceeds 1.4 grams/kg body weight/day during the higher-protein period.
32. The method of clause 1, wherein the person's dietary intake of protein exceeds 1.6 grams/kg body weight/day during the higher-protein period.
33. The method of clause 1, wherein the person's dietary intake of protein exceeds 1.8 grams/kg body weight/day during the higher-protein period. 34. The method of clause 1, wherein the person's dietary intake of protein exceeds 2.0 grams/kg body weight/day during the higher-protein period.
35. The method of clause 1, wherein the person's dietary intake of protein exceeds 50 grams per day during the higher-protein period.
36. The method of clause 1, wherein the person's dietary intake of protein exceeds 60 grams per day during the higher-protein period.
37. The method of clause 1, wherein the person's dietary intake of protein exceeds 70 grams per day during the higher-protein period.
38. The method of clause 1, wherein the person's dietary intake of protein exceeds 80 grams per day during the higher-protein period.
39. The method of clause 1, wherein the person's dietary intake of protein exceeds 90 grams per day during the higher-protein period.
40. The method of clause 1, wherein the person's dietary intake of protein exceeds 100 grams per day during the higher-protein period.
41. The method of clause 1, wherein the higher-protein period is no more than 14 days.
42. The method of clause 1, wherein the higher-protein period is no more than 10 days.
43. The method of clause 1, wherein the higher-protein period is no more than 7 days.
44. The method of clause 1, wherein the higher-protein period is no more than 6 days.
45. The method of clause 1, wherein the higher-protein period is no more than 5 days.
46. The method of clause 1, wherein the higher-protein period is no more than 4 days.
47. The method of clause 1, wherein the higher-protein period is no more than 3 days.
48. The method of clause 1, wherein the higher-protein period is no more than 2 days.
49. The method of clause 1, wherein the higher-protein period is no more than 1 day.
50. A system for preventing and/or treating disease, comprising:
food; and
instructions that a person eat the food according to the following: (i) during a lower-protein period of at least two days, the person eats a lower-protein portion of the food, such that the person's dietary intake of protein is restricted to less than 40 grams per day; and
(ii) during a higher-protein period after the lower-protein period, the person eats a higher-protein portion of the food, such that the person's dietary intake of protein exceeds 40 grams per day.
51. The system of clause 50, wherein the instructions further instruct that after the higher-protein period, the person repeat (i) and (ii).
52. The system of clause 50, wherein the food is substantially liquid.
53. The system of clause 50, wherein the food contains sufficient carbohydrate to prevent a negative nitrogen balance exceeding 5 grams of nitrogen per day in a person eating the food according to the instructions.
54. The system of clause 50, wherein the food contains sufficient carbohydrate to prevent a negative nitrogen balance exceeding 10 grams of nitrogen per day in a person eating the food according to the instructions.
55. The system of clause 50, wherein each of the lower-protein portion and the higher-protein portion comprise a plurality of meals configured to be provided to the person.
56. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to be restricted to less than 0.6 grams/kg body weight/day during the lower- protein period.
57. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to be restricted to less than 30 grams per day during the lower-protein period.
58. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to be restricted to less than 20 grams per day during the lower-protein period.
59. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to be restricted to less than 10 grams per day during the lower-protein period.
60. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to be restricted to less than 5 grams per day during the lower-protein period.
61. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to be restricted to about zero grams per day during the lower-protein period. 62. The system of clause 50, wherein the lower- -protein period is at least 3 days.
63. The system of clause 50, wherein the lower- -protein period is at least 4 days.
64. The system of clause 50, wherein the lower- -protein period is at least 5 days.
65. The system of clause 50, wherein the lower- -protein period is at least 6 days.
66. The system of clause 50, wherein the lower- -protein period is at least 7 days.
67. The system of clause 50, wherein the lower- -protein period is at least 8 days.
68. The system of clause 50, wherein the lower- -protein period is at least 9 days.
69. The system of clause 50, wherein the lower- -protein period is at least 10 days
70. The system of clause 50, wherein the lower- -protein period is at least 14 days
71. The system of clause 50, wherein the lower- -protein period is at least 21 days
72. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to exceed 0.8 grams/kg body weight/day during the higher-protein period.
73. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to exceed 1.0 grams/kg body weight/day during the higher-protein period.
74. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to exceed 1.2 grams/kg body weight/day during the higher-protein period.
75. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to exceed 1.4 grams/kg body weight/day during the higher-protein period.
76. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to exceed 1.6 grams/kg body weight/day during the higher-protein period.
77. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to exceed 50 grams per day during the higher-protein period.
78. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to exceed 60 grams per day during the higher-protein period.
79. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to exceed 70 grams per day during the higher-protein period.
80. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to exceed 80 grams per day during the higher-protein period.
81. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to exceed 90 grams per day during the higher-protein period. 82. The system of clause 50, wherein the instructions provide for the person's dietary intake of protein to exceed 100 grams per day during the higher-protein period.
83. The system of clause 50, wherein the higher-protein period is no more than 14 days.
84. The system of clause 50, wherein the higher-protein period is no more than 10 days.
85. The system of clause 50, wherein the higher-protein period is no more than 7 days.
86. The system of clause 50, wherein the higher-protein period is no more than 6 days.
87. The system of clause 50, wherein the higher-protein period is no more than 5 days.
88. The system of clause 50, wherein the higher-protein period is no more than 4 days.
89. The system of clause 50, wherein the higher-protein period is no more than 3 days.
90. The system of clause 50, wherein the higher-protein period is no more than 2 days.
91. The system of clause 50, wherein the higher-protein period is no more than 1 day.
92. A system for preventing and/or treating disease, comprising:
food comprising higher-protein meals and lower-protein meals; and instructions that a person eat the food as follows:
(i) during a lower-protein period of at least two days, the person eats the lower-protein meals such that the person's dietary intake of protein is restricted to less than 30 grams per day; and
(ii) during a higher-protein period that follows the lower-protein period and is no more than seven days, the person eats the higher-protein meals such that the person's dietary intake of protein exceeds 50 grams per day.
93. The system of clause 92, wherein the instructions further instruct that after the higher-protein period, the person repeat (i) and (ii). 94. The system of clause 92, wherein the lower-protein meals contain sufficient carbohydrate to prevent a negative nitrogen balance exceeding 10 grams of nitrogen per day in a person eating the food according to the instructions.
95. The system of clause 92, wherein the lower-protein meals contain sufficient carbohydrate to prevent a negative nitrogen balance exceeding 5 grams of nitrogen per day in a person eating the food according to the instructions.
96. The system of clause 92, wherein the lower-protein meals and higher-protein meals are substantially liquid.
97. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) to a person selected for having at least one of overweight, obesity, hypertension, metabolic syndrome, type 2 diabetes, hyperinsulinemia, or glucose intolerance, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 40 grams per day during a lower-protein period of at least one day;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 40 grams per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
98. The method of clause 97, wherein the lower-protein period is at least two days.
99. The method of clause 97, wherein the diabetes comprises type 2 diabetes.
100. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) to a person selected for having at least one of Alzheimer's disease, a genetic predisposition to a familial Alzheimer's disease, or cognitive impairment, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 40 grams per day during a lower-protein period of at least one day;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 40 grams per day during a higher-protein period; and (iii) after the higher-protein period, repeating (i) and (ii).
101. The method of clause 100, wherein the lower-protein period is at least two days.
102. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) to a person selected for having at least one of a cancerous or a precancerous neoplasia, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 40 grams per day during a lower-protein period of at least one day;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 40 grams per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
103. The method of clause 102, wherein the lower-protein period is at least two days.
104. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) to a person selected for having an infection by at least one of a bacterium, a virus, a fungus, or a prion, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 40 grams per day during a lower-protein period of at least one day;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 40 grams per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
105. The method of clause 104, wherein the lower-protein period is at least two days.
106. The method of clause 104, wherein the person is infected with Mycobacterium tuberculosis.
107. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) selecting a person having an autoimmune disorder; (ii) administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 40 grams per day during a lower-protein period of at least one day;
(iii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 40 grams per day during a higher-protein period; and
(iv) after the higher-protein period, repeating (i) and (ii).
108. The method of clause 105, wherein the lower-protein period is at least two days.
109. The method of clause 105, wherein the autoimmune disorder comprises at least one of thyroiditis, hyperthyroidism, or hypothyroidism.
110. The method of clause 105, wherein the autoimmune disorder comprises a Human Leukocyte Antigen (HLA) B27 associated disease.
111. The method of clause 105, wherein the autoimmune disorder comprises multiple sclerosis.
112. The method of clause 105, wherein the autoimmune disorder comprises at least one of rheumatoid arthritis, ankylosing spondylitis, an anterior uveitis, or psoriatic arthritis.
113. The method of clause 105, wherein the autoimmune disorder comprises type 1 diabetes.
114. The method of clause 105, wherein the autoimmune disorder comprises Crohn's disease.
115. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) selecting a person having at least one of an inflammatory bowel disease or an increased risk of an inflammatory bowel disease;
(ii) administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 40 grams per day during a lower-protein period of at least one day;
(iii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 40 grams per day during a higher-protein period; and (iv) after the higher-protein period, repeating (i) and (ii).
116. The method of clause 115, wherein the lower-protein period is at least two days.
117. The method of clause 115, wherein the inflammatory bowel disease comprises Crohn's disease.
118. The method of clause 115, wherein the inflammatory bowel disease comprises ulcerative colitis.
119. A method of slowing a rate of accumulation of mitochondrial damage in a mammal, comprising:
(i) administering nutrients to the mammal such that the mammal's bodily intake of protein is restricted to less than 40 grams per day during a lower-protein period of at least one day;
(iii) after the lower-protein period, administering nutrients to the mammal such that the mammal's bodily intake of protein exceeds 40 grams per day during a higher- protein period; and
(iv) after the higher-protein period, repeating (i) and (ii).
120. The method of clause 119, wherein the lower-protein period is at least two days.
121. The method of clause 119, wherein the damage comprises DNA oxidation.
122. The method of clause 119, wherein the damage comprises a DNA mutation.
123. The method of clause 119, wherein the damage comprises an RNA mutation.
124. A system for preventing and/or treating disease, comprising:
nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising (a) at least one of lipid or carbohydrate and (b) at least one higher-protein portion and at least one lower-protein portion;
wherein the material is configured to be administered to the person in the following sequence:
(i) during a lower-protein period of at least two days, the person receives the at least one lower-protein portion such that the person's bodily intake of protein is restricted to less than 0.4 mg/kg of the person's bodyweight per day; and (ii) during a higher-protein period that is after the lower-protein period and is at least one day, the person receives the at least one higher-protein portion such that the person's bodily intake of protein exceeds 0.6 mg/kg of the person's bodyweight per day.
125. The system of clause 124, further comprising instructions that the material be administered according to the sequence.
126. The system of clause 124, wherein the material is configured to be administered to the person orally.
127. The system of clause 124, wherein the material is configured to be administered to the person parenterally.
128. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) administering nutrients to a person such that the person's bodily intake of protein is restricted to less than 40 grams per day during a lower-protein period of at least two days;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 40 grams per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
129. The method of clause 128, wherein the administering during at least one of the lower-protein period or the higher-protein period is configured for oral ingestion of nutrients by the person.
130. The method of clause 128, wherein the administering during at least one of the lower-protein period or the higher-protein period comprises parenteral administration of nutrients to the person.
131. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) administering nutrients to a person such that the person's bodily intake of protein is restricted to less than 0.4 mg/kg of the person's bodyweight per day during a lower-protein period of at least two days; (ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 0.6 mg/kg of the person's bodyweight per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
132. The method of clause 131, wherein the administering during at least one of the lower-protein period or the higher-protein period is configured for oral ingestion of nutrients by the person.
133. The method of clause 131, wherein the administering during at least one of the lower-protein period or the higher-protein period comprises parenteral administration of nutrients to the person.
134. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) administering nutrients to a person such that the person's bodily intake of protein is restricted to less than the U.S. recommended daily intake of protein during a lower-protein period of at least two days;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein meets or exceeds the U.S. recommended daily intake of protein during a higher-protein period of at least two days; and
(iii) after the higher-protein period, repeating (i) and (ii).
135. The method of clause 134, wherein the administering during at least one of the lower-protein period or the higher-protein period is configured for oral ingestion of nutrients by the person.
136. The method of clause 134, wherein the administering during at least one of the lower-protein period or the higher-protein period comprises parenteral administration of nutrients to the person.
137. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) to a person selected for having, or being at risk for, age-related macular degeneration, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 40 grams per day during a lower-protein period of at least one day;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 40 grams per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
138. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) to a person selected for having age-related macular degeneration, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 0.4 mg/kg of the person's bodyweight per day during a lower-protein period of at least one day;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 0.6 mg/kg of the person's bodyweight per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
139. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) to a person selected for having had an ischemic impairment of the person's neurologic function, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 0.4 mg/kg of the person's bodyweight per day during a lower-protein period of at least one day;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 0.6 mg/kg of the person's bodyweight per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
140. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) to a person selected for having an atrial dysrhythmia, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 0.4 mg/kg of the person's bodyweight per day during a lower-protein period of at least one day;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 0.6 mg/kg of the person's bodyweight per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
141. The method of clause 140, wherein the atrial dysrhythmia comprises at least one of atrial fibrillation or atrial flutter.
142. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) to a person selected for having a ventricular dysrhythmia, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 0.4 mg/kg of the person's bodyweight per day during a lower-protein period of at least one day;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 0.6 mg/kg of the person's bodyweight per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
143. The method of clause 142, wherein the ventricular dysrhythmia comprises at least one of ventricular fibrillation or ventricular tachycardia.
144. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) to a person selected for having a ventricular dysrhythmia, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 0.4 mg/kg of the person's bodyweight per day during a lower-protein period of at least one day;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 0.6 mg/kg of the person's bodyweight per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii). 145. The method of clause 142, wherein the ventricular dysrhythmia comprises at least one of ventricular fibrillation or ventricular tachycardia.
146. A method for providing nutrients to a person to maintain or enhance health, comprising:
to a person selected for having, or being at risk for, male pattern baldness, providing nutrient material administrable to at least one of the person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
wherein all of any protein in the material constitutes less than 5 percent of a caloric content of the material;
instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 30 grams per day during a lower- protein time period of at least 48 hours.
instructing that carbohydrate be, or may be, administered to the person such that the person's bodily intake of carbohydrate is at least 40 grams per day during the lower- protein period; and
instructing that, during a higher-protein time period that is after the lower-protein period and is at least 24 hours, the person receives a higher bodily intake of protein than the person received during the lower-protein period.
147. A method for providing nutrients to a person to maintain or enhance health, comprising:
providing nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
wherein all of any protein in the material constitutes less than 5 percent of a caloric content of the material;
instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 30 grams per day during a lower- protein time period of at least 48 hours. instructing that carbohydrate be, or may be, administered to the person such that the person's bodily intake of carbohydrate is at least 40 grams per day during the lower- protein period; and
instructing that, during a higher-protein time period that is after the lower-protein period and is at least 24 hours, the person receives a higher bodily intake of protein than the person received during the lower-protein period.
148. The method of clause 147, further comprising instructing that the person receives an average daily bodily intake of all protein during the higher-protein period that is at least 40 grams.
149. The method of clause 147, further comprising instructing that no substantial source of protein be administered to the person during the lower-protein period.
150. The method of clause 147, further comprising instructing that the person's bodily intake of carbohydrate be restricted to less than 60 grams per day during the higher-protein period.
151. The method of clause 147, further comprising instructing that the person's bodily intake of carbohydrate be restricted to less than 50 grams per day during the higher-protein period.
152. The method of clause 147, further comprising instructing that the person's bodily intake of carbohydrate be restricted to less than 40 grams per day during the higher-protein period.
153. The method of clause 147, further comprising instructing that the person's bodily intake of carbohydrate be restricted to less than 30 grams per day during the higher-protein period.
154. The method of clause 147, further comprising instructing that the person's bodily intake of carbohydrate be restricted to less than 20 grams per day during the higher-protein period.
155. The method of clause 147, further comprising instructing that the person's bodily intake of carbohydrate be restricted to less than 10 grams per day during the higher-protein period. 156. The method of clause 147, further comprising instructing that the person's bodily intake of carbohydrate be restricted to substantially zero grams per day during the higher-protein period.
157. The method of clause 147, wherein the material comprises at least some of the carbohydrate administered to the person during the lower-protein period.
158a. The method of clause 147, wherein the providing the material comprises providing individually packaged servings of the material, and the all of any protein in the material constitutes no more than 15 grams per serving.
158b. The method of clause 147, wherein the providing the material comprises providing individually packaged servings of the material, and the all of any protein in the material constitutes no more than 10 grams per serving.
158c. The method of clause 147, wherein the providing the material comprises providing individually packaged servings of the material, and the all of any protein in the material constitutes no more than 5 grams per serving.
158d. The method of clause 147, wherein the providing the material comprises providing individually packaged servings of the material, and the all of any protein in the material constitutes about zero grams per serving.
159. The method of clause 147, wherein the material is configured to be administered to the person orally.
160. The method of clause 147, wherein the material is configured to be administered to the person parenterally.
161. The method of clause 147, wherein material comprises carbohydrate, and the instructing that carbohydrate be, or may be, administered to the person comprises instructing that the material be administered to the person such that the person's bodily intake of carbohydrate in the material is at least 40 grams per day during the lower-protein period.
162. The method of clause 147, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 20 grams per day during the lower-protein period. 163. The method of clause 147, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 10 grams per day during the lower-protein period.
164. The method of clause 147, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to about zero grams per day during the lower-protein period.
165 a. The method of clause 147, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 0.1 g per kilogram of the person's bodyweight per day during the lower-protein period.
165b. The method of clause 147, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 0.2 g per kilogram of the person's bodyweight per day during the lower-protein period.
165c. The method of clause 147, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 0.3 g per kilogram of the person's bodyweight per day during the lower-protein period.
165d. The method of clause 147, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 0.4 g per kilogram of the person's bodyweight per day during the lower-protein period.
165e. The method of clause 147, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 0.5 g per kilogram of the person's bodyweight per day during the lower-protein period.
166. The method of clause 147, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 50 grams.
167. The method of clause 147, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 60 grams.
168. The method of clause 147, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 70 grams.
169. The method of clause 147, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.5 g per kilogram of the person's body weight. 170. The method of clause 147, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.6 g per kilogram of the person's body weight.
171. The method of clause 147, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.7 g per kilogram of the person's body weight.
172. The method of clause 147, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.8 g per kilogram of the person's body weight.
173. The method of clause 147, wherein the lower-protein period is at least 3 days.
174. The method of clause 147, wherein the lower-protein period is at least 4 days.
175. The method of clause 147, wherein the lower-protein period is at least 5 days.
176. The method of clause 147, wherein the lower-protein period is at least 6 days.
177. The method of clause 147, wherein the lower-protein period is at least 7 days.
178. The method of clause 147, wherein the higher-protein period is no more than 14 days.
179. The method of clause 147, wherein the higher-protein period is no more than 10 days.
180. The method of clause 147, wherein the higher-protein period is no more than 7 days.
181. The method of clause 147, wherein the higher-protein period is no more than 6 days.
182. The method of clause 147, wherein the higher-protein period is no more than 5 days.
183. The method of clause 147, wherein the higher-protein period is no more than 4 days.
184. The method of clause 147, wherein the higher-protein period is no more than 3 days.
185. The method of clause 147, wherein the higher-protein period is no more than 2 days. 186. A method for providing nutrients to a person to maintain or enhance health, comprising:
providing nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
wherein all of any protein in the material constitutes less than 5 percent of a caloric content of the material;
instructing that the material be administered to the person such that the person's bodily intake of at least one of protein, peptides, or amino acids is restricted to less than 30 grams per day during a lower-protein time period of at least 48 hours;
instructing that carbohydrate be, or may be, administered to the person such that the person's bodily intake of carbohydrate is at least 40 grams per day during the lower- protein period; and
instructing that, during a higher-protein time period that is after the lower-protein period and is at least 24 hours, the person receives a higher bodily intake of protein than the person received during the lower-protein period, such that the average daily bodily intake of all protein during the higher-protein period is at least 40 grams.
187. A method for providing nutrients to a person to maintain or enhance health, comprising:
providing nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
wherein all of any protein in the material constitutes less than 5 percent of a caloric content of the material;
instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 30 grams per day during a lower- protein time period of at least 48 hours;
instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 40 grams per day, and is not limited to 150 grams per day, during the lower-protein period; and instructing that, during a higher-protein time period that is after the lower-protein period and is at least 24 hours, the person receives a higher bodily intake of protein than the person received during the lower-protein period.
188. The method of clause 187, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is not limited to 200 grams per day during the lower-protein period.
189. The method of clause 187, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is not limited to 250 grams per day during the lower-protein period.
190. The method of clause 187, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is not limited to 300 grams per day during the lower-protein period.
191. The method of clause 187, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is not limited to 350 grams per day during the lower-protein period.
192. The method of clause 187, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is not limited to 400 grams per day during the lower-protein period.
193. The method of clause 187, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is not limited to 500 grams per day during the lower-protein period.
194. The method of clause 187, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is not limited to 600 grams per day during the lower-protein period.
195. The method of clause 187, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is not limited to 700 grams per day during the lower-protein period.
196. A method for providing nutrients to a person to maintain or enhance health, comprising: (a) providing nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
(b) wherein all of any protein in the material constitutes no more than 10 percent of a caloric content of the material;
(c) instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 30 grams per day during a lower-protein time period of at least 48 hours;
(d) instructing that nutrition be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 40% of the person's bodily intake of calories during the lower-protein period; and
(e) instructing that, during a higher-protein time period that is after the lower- protein period and is at least 24 hours, the person receives a higher daily bodily intake of protein than the person received during the lower-protein period.
196a. The method of clause 196, further comprising repeating steps (c) and (e).
196aa. The method of clause 196, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 5 percent of the person's bodily intake of calories during the lower-protein.
196b. The method of clause 196, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 10 percent of the person's bodily intake of calories during the lower-protein.
196c. The method of clause 196, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 15 percent of the person's bodily intake of calories during the lower-protein.
196d. The method of clause 196, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 20 percent of the person's bodily intake of calories during the lower-protein.
196e. The method of clause 196, wherein the all of any protein in the material constitutes no more than 8 percent of the caloric content of the material. 196f. The method of clause 196, wherein the all of any protein in the material constitutes no more than 5 percent of the caloric content of the material.
196g. The method of clause 196, wherein the all of any protein in the material constitutes no more than 3 percent of the caloric content of the material.
197. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 50 percent of the person's bodily intake of calories during the lower-protein period.
198. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 60 percent of the person's bodily intake of calories during the lower-protein period.
199. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 70 percent of the person's bodily intake of calories during the lower-protein period.
200. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 80 percent of the person's bodily intake of calories during the lower-protein period.
201. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 90 percent of the person's bodily intake of calories during the lower-protein period.
202. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 40 grams per day during the lower-protein period.
203. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 60 grams per day during the lower-protein period.
204. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 80 grams per day during the lower-protein period. 205. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 100 grams per day during the lower-protein period.
206. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 120 grams per day during the lower-protein period.
207. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 140 grams per day during the lower-protein period.
208. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 160 grams per day during the lower-protein period.
209. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 180 grams per day during the lower-protein period.
210. The method of clause 196, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 200 grams per day during the lower-protein period.
211. The method of clause 196, wherein carbohydrate in the material constitutes at least 50 percent of the caloric content of the material.
212. The method of clause 196, wherein carbohydrate in the material constitutes at least 60 percent of the caloric content of the material.
213. The method of clause 196, wherein carbohydrate in the material constitutes at least 70 percent of the caloric content of the material.
214. The method of clause 196, wherein carbohydrate in the material constitutes at least 80 percent of the caloric content of the material.
215. The method of clause 196, wherein carbohydrate in the material constitutes at least 90 percent of the caloric content of the material. 216. The method of clause 196, further comprising instructing that the person receives an average daily bodily intake of all protein during the higher-protein period that is at least 40 grams.
217. The method of clause 196, further comprising instructing that no substantial source of protein be administered to the person during the lower-protein period.
218. The method of clause 196, wherein the material comprises at least some of the carbohydrate administered to the person during the lower-protein period.
219. The method of clause 196, wherein the providing the material comprises providing individually packaged servings of the material, and the all of any protein in the material constitutes no more than 15 grams per serving.
220. The method of clause 196, wherein the material is configured to be administered to the person orally.
221. The method of clause 196, wherein the material is configured to be administered to the person parenterally.
222. The method of clause 196, wherein material comprises carbohydrate, and further comprising instructing that the material be administered to the person such that the person's bodily intake of carbohydrate in the material is at least 40 grams per day during the lower-protein period.
223. The method of clause 196, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 20 grams per day during the lower-protein period.
224. The method of clause 196, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 10 grams per day during the lower-protein period.
225. The method of clause 196, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to about zero grams per day during the lower-protein period.
226. The method of clause 196, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 0.3 g per kilogram of the person's bodyweight per day during the lower-protein period. 227. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 40 grams.
228. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 50 grams.
229. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 60 grams.
230. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 70 grams.
231. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.5 g per kilogram of the person's body weight.
232. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.6 g per kilogram of the person's body weight.
233. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.7 g per kilogram of the person's body weight.
234. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.8 g per kilogram of the person's body weight.
235. The method of clause 196, wherein the lower-protein period is at least 3 days.
236. The method of clause 196, wherein the lower-protein period is at least 4 days.
237. The method of clause 196, wherein the lower-protein period is at least 5 days.
238. The method of clause 196, wherein the lower-protein period is at least 6 days.
239. The method of clause 196, wherein the lower-protein period is at least 7 days.
240. The method of clause 196, wherein the higher-protein period is no more than 14 days.
241. The method of clause 196, wherein the higher-protein period is no more than 10 days. 242. The method of clause 196, wherein the higher-protein period is no more than 7 days.
243. The method of clause 196, wherein the higher-protein period is no more than 6 days.
244. The method of clause 196, wherein the higher-protein period is no more than 5 days.
245. The method of clause 196, wherein the higher-protein period is no more than 4 days.
246. The method of clause 196, wherein the higher-protein period is no more than 3 days.
247. The method of clause 196, wherein the higher-protein period is no more than 2 days.
248. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives, within a period of 6 hours or less, at least 90 percent of a bodily intake of all protein received in a day.
249. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives, within a period of 5 hours or less, at least 90 percent of a bodily intake of all protein received in a day.
250. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives, within a period of 4 hours or less, at least 90 percent of a bodily intake of all protein received in a day.
251. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives, within a period of 3 hours or less, at least 90 percent of a bodily intake of all protein received in a day.
252. The method of clause 196, further comprising instructing that, during the higher- protein period, the person receives, within a period of 2 hours or less, at least 90 percent of a bodily intake of all protein received in a day.
253. A method of reducing at least one of a likelihood or a severity of disease, comprising: (i) to a person selected for having at least one of osteoporosis, osteopenia, or a significant risk of osteoporosis, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 30 grams per day during a lower- protein period of at least one day;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 40 grams per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
254. A method of reducing at least one of a likelihood or a severity of disease, comprising:
(i) to a person selected for having chronic kidney disease, administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 30 grams per day during a lower-protein period of at least one day;
(ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 40 grams per day during a higher-protein period; and
(iii) after the higher-protein period, repeating (i) and (ii).
Dl. A method for providing nutrients to a person to slow, prevent, and or treat at least one of neurodegenerative disease, autoimmune disease, infection, glaucoma, macular degeneration, type 2 diabetes, type 1 diabetes, cancer, atherosclerotic disease, cardiomyopathy, liver disease, kidney disease, insulin resistance, osteoporosis, psychiatric disorders, obesity, or metabolic syndrome, comprising:
providing nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
wherein all of any protein in the material constitutes no more than 5 percent of a caloric content of the material;
instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 30 grams per day during a lower- protein time period of at least 48 hours; instructing that nutrition be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 40 percent of the person's bodily intake of energy during the lower-protein period; and
instructing that, during a higher-protein time period that is after the lower-protein period and is at least 24 hours and no more than 30 days, the person receives a higher daily bodily intake of protein than the person received during the lower-protein period. D2. The method of any of clause Dl, further comprising not instructing that the person's caloric intake be restricted during at least one of the lower-protein period or the higher- protein period.
D3. The method of any of the clauses herein, wherein the nutrient material comprises at least one of an omega-3 or an omega-6 fatty acid.
D4. The method of any of the clauses herein, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 60 percent of the person's bodily intake of calories during the lower-protein period.
D5. The method of clause Dl, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 80 percent of the person's bodily intake of calories during the lower-protein period.
D6. The method of clause Dl, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 100 grams per day during the lower-protein period.
D7. The method of clause Dl, wherein carbohydrate in the material constitutes at least 50 percent of the caloric content of the material.
D8. The method of clause Dl, wherein carbohydrate in the material constitutes at least 90 percent of the caloric content of the material.
D9. The method of clause Dl, further comprising instructing that the person receives an average daily bodily intake of all protein during the higher-protein period that is at least 40 grams.
D10. The method of clause Dl, wherein the material comprises at least some of the carbohydrate instructed to be administered to the person during the lower-protein period. Dl l. The method of clause Dl, wherein the providing the material comprises providing individually packaged servings of the material, and the all of any protein in the material constitutes no more than 15 grams per serving.
D12. The method of clause Dl, wherein the material comprises carbohydrate, and further comprising instructing that the material be administered to the person such that the person's bodily intake of carbohydrate in the material is at least 40 grams per day during the lower-protein period.
D13. The method of clause Dl, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 10 grams per day during the lower-protein period.
D14. The method of clause Dl, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 0.3 g per kilogram of the person's bodyweight per day during the lower-protein period.
15. The method of clause Dl, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 50 grams.
D16. The method of clause Dl, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.6 g per kilogram of the person's body weight.
D17. The method of clause Dl, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.8 g per kilogram of the person's body weight.
D18. The method of clause Dl, wherein the lower-protein period is at least 3 days.
D19. The method of clause Dl, wherein the lower-protein period is at least 4 days.
D20. The method of clause Dl, wherein the higher-protein period is no more than 5 days.
D21. The method of clause Dl, wherein the higher-protein period is no more than 3 days.
D22. The method of clause Dl, further comprising instructing that, during the higher- protein period, the person receives, within a period of 4 hours or less, at least 90 percent of a bodily intake of all protein received in a day. D23. The method of clause Dl, wherein leucine and glutamine are substantially absent in the nutrient material.
D24. The method of clause D23, wherein arginine is substantially absent in the nutrient material.
D25. The method of clause D23, wherein methionine is substantially absent in the nutrient material.
D26. The method of clause Dl, wherein methionine is substantially absent in the nutrient material.
D27. The method of clause Dl, wherein a concentration of leucine and a concentration of glutamine in the nutrient material are each lower than are concentrations of other amino acids in the nutrient material.
D28. The method of clause Dl, wherein leucine and glutamine are substantially absent in the nutrient material, and another amino acid is present in the nutrient material.
D29. The method of clause 30, wherein methionine is substantially absent in the nutrient material.
D30. The method of clause D23, wherein a concentration of methionine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
D31. The method of clause 23, wherein a concentration of arginine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
D32. The method of clause Dl, wherein a concentration of leucine and a concentration of glutamine in the nutrient material are each lower than are concentrations of other amino acids in the nutrient material.
D33. The method of clause Dl, wherein a concentration of leucine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
D34. The method of clause Dl, wherein a concentration of glutamine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
D35. The method of clause D23, wherein a concentration of methionine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
D36. The method of clause D23, wherein a concentration of arginine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material. D37. The method of clause Dl, wherein the nutrient material is more restricted in leucine and glutamine content than in the content of other amino acids.
D38. Nutrient material for use to slow, prevent, and/or treat at least one of neurodegenerative disease, autoimmune disease, infection, glaucoma, macular degeneration, type 2 diabetes, type 1 diabetes, cancer, atherosclerotic disease, cardiomyopathy, liver disease, kidney disease, insulin resistance, osteoporosis, psychiatric disorders, obesity, or metabolic syndrome, by administration to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
wherein all of any protein in a first portion of the material constitutes no more than 5 percent of a caloric content of the material;
wherein all of any protein in a second portion of the material constitutes at least 10 percent of a caloric content of the material; and
wherein the use is such that:
(a) the first portion is administered to the person such that person's bodily intake of all protein is restricted to less than 30 grams per day during a lower-protein time period of at least 48 hours;
(b) nutrition is administered to the person such that the person's bodily intake of carbohydrate constitutes at least 40 percent of the person's bodily intake of energy during the lower-protein period; and
(c) the second portion is administered to the person during a higher-protein time period that is after the lower-protein period and is at least 24 hours and no more than 14 days, such that the person receives a higher daily bodily intake of protein than the person received during the lower-protein period.
D39. The nutrient material of clause D38, wherein the use is such that the person's caloric intake is not restricted during at least one of the lower-protein period or the higher-protein period.
D40. The nutrient material of clause D38, further comprising at least one of an omega-3 or an omega-6 fatty acid. D41. The nutrient material of clause D38, wherein the use is such that the person's bodily intake of carbohydrate constitutes at least 60 percent of the person's bodily intake of calories during the lower-protein period.
D42. The nutrient material of clause D38, wherein the use is such that the person's bodily intake of carbohydrate constitutes at least 80 percent of the person's bodily intake of calories during the lower-protein period.
D43. The nutrient material of clause D38, wherein the use is such that the person's bodily intake of carbohydrate is at least 100 grams per day during the lower-protein period.
D44. The nutrient material of clause D38, wherein carbohydrate in the material constitutes at least 50 percent of the caloric content of the material.
D45. The nutrient material of clause D38, wherein carbohydrate in the material constitutes at least 90 percent of the caloric content of the material.
D46. The nutrient material of clause D38, wherein the use is such that the average daily bodily intake of all protein during the higher-protein period that is at least 40 grams.
D47. The nutrient material of clause D38, wherein the use is such that at least some of the carbohydrate instructed to be administered to the person during the lower-protein period.
D48. The nutrient material of clause D38, comprising individually packaged servings of the material, wherein all of any protein in the material constitutes no more than 15 grams per serving.
D49. The nutrient material of clause D38, wherein the material comprises carbohydrate, and wherein the use is such that such that the person's bodily intake of carbohydrate in the material is at least 40 grams per day during the lower-protein period.
50. The nutrient material of clause D38, wherein the use is such that the person's bodily intake of all protein is restricted to less than 10 grams per day during the lower-protein period.
D51. The nutrient material of clause D38, wherein the use is such that the person's bodily intake of all protein is restricted to less than 0.3 g per kilogram of the person's bodyweight per day during the lower-protein period.
D52. The nutrient material of clause D38, wherein the use is such that, during the higher-protein period, the person receives a bodily intake of all protein of at least 50 grams. D53. The nutrient material of clause D38, wherein the use is such that, during the higher-protein period, the person receives a bodily intake of all protein of at least 0.6 g per kilogram of the person's body weight.
D54. The nutrient material of clause D38, wherein the use is such that, during the higher-protein period, the person receives a bodily intake of all protein of at least 0.8 g per kilogram of the person's body weight.
D55. The nutrient material of clause D38, wherein the lower-protein period is at least 3 days.
D56. The nutrient material of clause D38, wherein the lower-protein period is at least 4 days.
D57. The nutrient material of clause D38, wherein the higher-protein period is no more than 5 days.
D58. The nutrient material of clause D38, wherein the higher-protein period is no more than 3 days.
D59. The nutrient material of clause D38, wherein the use is such that, during the higher-protein period, the person receives, within a period of 4 hours or less, at least 90 percent of a bodily intake of all protein received in a day.
D60. The nutrient material of clause D38, wherein leucine and glutamine are substantially absent in the nutrient material.
D61. The nutrient material of clause D23, wherein arginine is substantially absent in the nutrient material.
D62. The nutrient material of clause D23, wherein methionine is substantially absent in the nutrient material.
D63. The nutrient material of clause D38, wherein methionine is substantially absent in the nutrient material.
D64. The nutrient material of clause D38, wherein a concentration of leucine and a concentration of glutamine in the nutrient material are each lower than are concentrations of other amino acids in the nutrient material. D65. The nutrient material of clause D38, wherein leucine and glutamine are substantially absent in the nutrient material, and another amino acid is present in the nutrient material.
D66. The nutrient material of clause D30, wherein methionine is substantially absent in the nutrient material.
D67. The nutrient material of clause D66, wherein a concentration of methionine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
D68. The nutrient material of clause D66, wherein a concentration of arginine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
D69. The nutrient material of clause D38, wherein a concentration of leucine and a concentration of glutamine in the nutrient material are each lower than are concentrations of other amino acids in the nutrient material.
D70. The nutrient material of clause D38, wherein a concentration of leucine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
D71. The nutrient material of clause D38, wherein a concentration of glutamine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
D72. The nutrient material of clause D66, wherein a concentration of methionine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
D73. The nutrient material of clause D66, wherein a concentration of arginine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
D74. The nutrient material of clause D38, wherein the nutrient material is more restricted in leucine and glutamine content than in the content of other amino acids.
[0005] Additional features and advantages of the subject technology will be set forth in the description below, and in part will be apparent from the description, or may be learned by practice of the subject technology. The advantages of the subject technology will be realized and attained by the structure particularly pointed out in the written description and claims hereof as well as the appended drawings.
[0006] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the subject technology as claimed. Detailed Description
[0007] In the following detailed description, numerous specific details are set forth to provide a full understanding of the subject technology. It will be apparent, however, to one ordinarily skilled in the art that the subject technology may be practiced without some of these specific details. In other instances, well-known structures and techniques have not been shown in detail so as not to obscure the subject technology.
[0008] A phrase such as "an aspect" does not imply that such aspect is essential to the subject technology or that such aspect applies to all configurations of the subject technology. A disclosure relating to an aspect may apply to all configurations, or one or more configurations. An aspect may provide one or more examples of the disclosure. A phrase such as "an aspect" may refer to one or more aspects and vice versa. A phrase such as "an embodiment" does not imply that such embodiment is essential to the subject technology or that such embodiment applies to all configurations of the subject technology. A disclosure relating to an embodiment may apply to all embodiments, or one or more embodiments. An embodiment may provide one or more examples of the disclosure. A phrase such "an embodiment" may refer to one or more embodiments and vice versa. A phrase such as "a configuration" does not imply that such configuration is essential to the subject technology or that such configuration applies to all configurations of the subject technology. A disclosure relating to a configuration may apply to all configurations, or one or more configurations. A configuration may provide one or more examples of the disclosure. A phrase such as "a configuration" may refer to one or more configurations and vice versa. To the extent permitted by law, the contents of this disclosure, including any figures and text, are protected under U.S. copyright law, copyright 2011, 2012.
[0009] Autophagy is a homeostatic "self-eating" process that has been conserved among eukaryotic cells and which involves the digestion of cytoplasmic components via the lysosomal pathway. Under normal conditions, it allows cells to break down long-lived proteins, thus complementing the action of the proteasome, which deals chiefly with short-lived proteins. During periods of starvation, stimulation of autophagy is important to provide cells exposed to nutrient deprivation with amino acids, glucose, and fatty acids to maintain metabolism and ATP levels compatible with cell survival. [0010] Stimulation of autophagy plays a critical role in counteracting nutrient deprivation following birth in newborn mice. Under basal conditions, autophagy helps the cell to get rid of damaged organelles, such as mitochondria and toxic aggregation-prone proteins. The functions of autophagy are not limited to these aspects, but extend beyond, as shown by the discovery of its role in the innate and adaptive immune responses. Autophagy malfunction contributes to the pathogenesis of a variety of diseases, including cancer, neurodegenerative and cardiovascular disorders, and infectious diseases. Another important aspect of autophagy in mammalian cells that remains to be unraveled is the role of autophagy in cell death, which has been the topic of several recent reviews.
[0011] During autophagy, part of the cytoplasm containing long-lived proteins or organelles is surrounded by a cisternal membrane, designated the phagophore by Seglen. The term "isolation membrane" is also used as a synonym of phagophore. The phagophore then closes to form a double-membraned vacuole, known as the autophagosome. Autophagosomes use dynein motors to move along microtubules towards the microtubule organizing center, where they fuse with lysosomes to form autolysosomes. However, most of the autophagosomes receive input from the endocytic compartments before they fuse with lysosomes.
[0012] Many AuTophaGy-related (ATG) genes identified in yeast by genetic screens have mammalian counterparts, and 18 different Atg proteins are known to be recruited to the isolation membrane, where they are involved in autophagosome formation. The origin of the membranes involved in autophagosome formation is unknown, but findings suggest the endoplasmic reticulum (ER) may be the source of lipids in the autophagosomal membranes. Ktistakis and colleagues propose that autophagosomes are formed in a high-phosphatidylinositol 3-phosphate (Ptdlns 3P), cup-shaped compartment known as the "omegasome" (from its omegalike shape), which is dynamically connected to the ER. Electron tomography analyses demonstrate a direct connection between the ER and the phagophore.
[0013] Evidence supports the idea that autophagy can be regulated at several different physiologic levels: (1) signaling pathways acting upstream of the autophagy machinery; (2) formation of autophagosomes; and (3) maturation of autophagosomes and their fusion with lysosomes. [0014] The existence of these different levels of autophagy regulation means that there are many different ways in which autophagy can be modulated by compounds relevant to clinical interventions. Moreover, the structural biology of Atg proteins is an expanding area of research that should not only reveal the mechanism of action of these proteins, but also guide the design of drugs intended to modulate their activity.
[0015] Autophagy refers to the process by which lysosomes degrade intracellular constituents, including both organelles and soluble proteins. This process is traditionally regarded as a cellular response to stress typically related to nutrient deprivation, toxin exposure, infection, or oxidative stress.
[0016] In contrast to the ubiquitin-proteasome pathway which degrades mostly shortlived proteins, autophagy is mainly involved in breaking down proteins with long-half lives and damaged organelles. Some basic form of this machinery is highly conserved from yeast to mammals. Depending on how lysosomes receive the cargo, autophagy can be further classified into three types, namely macroautophagy, microautophagy, and chaperone-mediated autophagy (CM A).
[0017] Macroautophagy involves multiple steps beginning with induction and ending with the release of the degraded products to the cytosol. It is characterized by the sequestration of cytosolic components in an autophagic vacuole or autophagosome, which fuses with lysosomal membrane to deliver its contents for degradation.
[0018] This double-membrane vacuole is the morphological hallmark of autophagy. The process is highly inducible in response to stress signals and regulated at various junctures by a large number of autophagy-related (ATG) genes, which involves controlling the activity of mTOR (mammalian target of rapamycin), a suppressor of macroautophagy. Microautophagy is less well studied than macroautophagy. Unlike macroautophagy, microautophagy does not involve the formation of double-membrane vacuoles.
[0019] Rather, the defining feature of microautophagy is the invagination or exvagination of lysosomal membrane to sequester cytosolic components. Mitophagy is a term describing the selective sequestration and removal of mitochondria by either macro- or microautophagy. [0020] Unlike macro- and microautophagy, CMA does not involve membrane vacuoles. Rather, it is regulated by direct protein interaction. Two key regulators, chaperone protein heat-shock cognate 70 (Hsc70) and lysosomal membrane receptor Lamp2A, control the CMA process.
[0021] Hsc70, in a complex with other co-chaperone proteins, binds to cytosolic proteins containing a pentapeptide targeting motif KFERQ and delivers substrate proteins to the surface of lysosomes. Binding of this chaperone-substrate complex to Lamp2A leads to the translocation of substrates cross the lysosomal membrane. Both the level and availability of Lamp2A are regulated by stress signals, making Lamp2A one of the major modes by which CMA activity is controlled.
[0022] Protein restriction, with or without caloric restriction, can affect disease states and the rate of aging in an organism, such as a human, in a variety of ways including, but not limited to, (a) reducing the rate of production of free radicals (as reactive oxygen species) in mitochondria, leading to reduced oxidation and mutation rates in mitochondrial DNA and RNA; (b) decreasing the degree of membrane fatty acid unsaturation in cells, including in the mitochondrial inner membrane, lowering the susceptibility of membranes to oxidative damage; and (c) increasing autophagy, to repair or replace cellular structures, such as damaged organelles and proteins.
[0023] According to aspects of the subject technology, a physician, other health care professional, or subject person can adjust the amount and duration of restriction and/or nonrestriction of protein administered to the person. By following principles of the subject technology as described herein, those of skill in the art can, without difficulty or undue experimentation, to adjust or titrate nutritional parameters, such as daily protein intake and the number of days of protein restriction, to optimize the attainment in the person of such endpoints as disease prevention or amelioration. This is accomplished by, for example, observing the effect of any significant change in a pattern of the person's protein intake over weeks to months. If signs of protein deficiency appear in the person, such as cold intolerance, hypoalbuminemia, or particular changes in skin, hair, and/or nails, an amount of protein administered to the person can easily be increased. [0024] According the subject technology, the degree of consumption or restriction of a person's protein (or other macronutrient) intake may be specified either in absolute or relative terms, such as by, e.g., daily or weekly total intake, or in mass or weight of protein per mass or weight of a person or her fat mass or her lean mass (e.g., mg of protein (or other macronutrient) per kg of the person's bodyweight). All claimed methods, compositions, and systems are intended to encompass any such type of specification. Thus, all methods and systems disclosed as one of the following two options (relative or absolute macronutrient intake) also includes the other:
[0025] First exemplary option: (i) during a lower-protein period, the person receives a lower-protein portion such that the person's bodily intake of protein is restricted to less than 0.4 mg/kg of the person's bodyweight per day; and (ii) during a higher-protein period that is after the lower-protein period, the person receives a higher-protein portion such that the person's bodily intake of protein exceeds 0.6 mg/kg of the person's bodyweight per day.
[0026] Second exemplary option: (i) administering nutrients to the person such that the person's bodily intake of protein is restricted to less than 40 grams per day during a lower- protein period of at least one day; and (ii) after the lower-protein period, administering nutrients to the person such that the person's bodily intake of protein exceeds 40 grams per day during a higher-protein period.
[0027] Some aspects of the subject technology include a method for providing nutrients to a person to maintain or enhance health, comprising: providing nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate; wherein all of any protein in the material constitutes less than 5 percent of a caloric content of the material; instructing that the material be administered to the person such that the person's bodily intake of at least one of protein, peptides, or amino acids is restricted to less than 30 grams per day during a lower-protein time period of at least 48 hours; instructing that carbohydrate be, or may be, administered to the person such that the person's bodily intake of carbohydrate is at least 40 grams per day during the lower-protein period; and instructing that, during a higher-protein time period that is after the lower-protein period and is at least 24 hours, the person receives a higher bodily intake of protein than the person received during the lower-protein period, such that the average daily bodily intake of all protein during the higher-protein period is at least 40 grams.
[0028] In some embodiments, the lower-protein period can be at least 24 hours, at least 36 hours, at least 72 hours, at least 96 hours, at least 120 hours, or similar minimum duration.
[0029] The inventor has found that autophagy in at least hepatocytes and neurons is unexpectedly stimulated to a beneficial degree during periods of dietary protein restriction despite a concomitant dietary carbohydrate intake of, e.g., at least 40 grams per day or at least 60 percent of total caloric intake, and despite its attendant elevation of insulin. Elevated insulin has been previously thought to prevent, generally uniformly, autophagy or to prevent substantial increases in autophagy.
[0030] In some embodiments, the lower-protein time period is at least 36 hours.
[0031] Autophagy and Parkinson's disease
[0032] Emerging evidence supports the view that dysregulation of autophagy may contribute to the pathogenic process in Parkinson's disease (PD). Several genetic risk factors associated with PD have been connected to different forms of autophagy. This includes evidence demonstrating that both macroautophagy and CMA regulate a-synuclein. Furthermore, the CMA process can be disrupted by the a-synuclein A53T mutant. Similarly, it has been shown that the ubiquitin C-terminal hydrolase LI (UCH-L1) mutant I94M interrupts the CMA process by binding to Lamp2A with abnormally high affinity. Parkin has been shown to be re-localized to mitochondria following mitochondrial damage, which promotes mitophagy.
[0033] LRRK2 mutants have been recently found to induce the increase or accumulation of autophagic vacuoles. Loss of PINK1 function has been proposed to affect autophagy.
[0034] Strong experimental and epidemiological data exist to support an etiological role for neurotoxins in PD. There are hints that many of these toxins may also alter the process of autophagy. For example, mitochondrial complex I inhibitor rotenone can inhibit capacity of autophagy. 6-OHDA up-regulates LC3 in nigral DA neurons. Paraquat induces the accumulation of autophagic vacuoles. [0035] These toxins may affect CMA. Some studies show that limited exposure to 6- OHDA activates CMA by increasing the levels of Lamp2A.
[0036] Intracellular protein misfolding and aggregation are features of many late- onset neurodegenerative diseases called proteinopathies. These include Alzheimer's disease, Parkinson's disease, tauopathies, and polyglutamine expansion diseases [e.g., Huntington's disease and various spinocerebellar ataxias (SCAs), like SCA3]. Outside of the subject technology, there are no known effective strategies to slow or prevent the neurodegeneration resulting from these diseases in humans. The mutations causing many proteinopathies (e.g., polyglutamine diseases and tauopathies) confer novel toxic functions on the specific protein, and disease severity frequently correlates with the expression levels of the protein. Thus, the factors regulating the synthesis and clearance of these aggregate-prone proteins are putative therapeutic targets. The proteasome and autophagy-lysosomal pathways are the major routes for mutant huntingtin fragment clearance. While the narrow proteasome barrel precludes entry of oligomers and aggregates of mutant huntingtin (or other aggregate-prone intracellular proteins), such substrates can be degraded by macroautophagy.
[0037] Rapamycin reduces levels of soluble and aggregated huntingtin and attenuates its toxicity in cells and in transgenic Drosophila and mouse models.
[0038] The range of intracellular proteinopathy substrates that are cleared by autophagy includes other targets, including proteins mutated in certain SCAs, forms of synuclein mutated in familial forms of Parkinson's disease, and tau mutants that cause frontotemporal dementia/tauopathy. This section discusses the therapeutic potential of autophagy upregulation for various proteinopathies, and describes how this strategy may act both by removing the primary toxin (the misfolded/aggregate-prone protein) and by reducing susceptibility to apoptotic insults.
[0039] Proteinopathies
[0040] Intracellular protein misfolding and aggregation are features of many late- onset neurodegenerative diseases called proteinopathies. These include Alzheimer's disease, Parkinson's disease, tauopathies, and various diseases caused by abnormally expanded tracts of the amino acid glutamine, like Huntington's disease (HD). HD is an autosomal-dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion, which results in an abnormally long polyglutamine (polyQ) tract in the N-terminus of huntingtin. Asymptomatic individuals have 35 or fewer CAG repeats, while HD is caused by expansions of 36 or more repeats.
[0041] HD belongs to a group of human neurodegenerative disorders caused by CAG repeat/polyQ expansions, which includes spinocerebellar ataxias (SCAs) type 1, 2, 3, 6, 7, and 17, spinobulbar muscular dystrophy (SBMA), and dentatorubral pallidoluysian atrophy (DRPLA).
[0042] Autophagy is a bulk degradation process that involves the sequestration of portions of cytoplasm by a double-membrane autophagosome, followed by digestion of the sequestered material when the autophagosome fuses with a lysosome full of hydrolytic enzymes.
[0043] Researchers have found that loss of autophagy causes neurodegeneration even in the absence of any disease-associated mutant proteins, which suggests that the continuous clearance of cellular proteins through basal autophagy prevents their accumulation, and in turn prevents neurodegeneration. Experiments in fly and mouse models have provided proof of principle that stimulation of autophagy can prevent and even reverse neurodegenerative disease.
[0044] The compound that has been used for such studies, the immunosuppressant rapamycin, stimulates autophagy and aggregate digestion by inhibiting the evolutionarily conserved protein kinase TOR (target of rapamycin). TOR acts as a brake on autophagy; thus, when it is inhibited with rapamycin, autophagy is turned on.
[0045] TOR does not control autophagy alone— it is also an activator of ribosome biogenesis and other pathways involved in cell growth. This causes undesired side effects, such as immunosuppression, during long-term administration of rapamycin, and therefore alternative inducers of autophagy are desired.
[0046] Dietary restriction of total calories without malnutrition has been shown to prolong life in rats, mice, dogs, fish, spiders, fleas, flies, worms, yeasts, and monkeys.
[0047] Dietary protein restriction can achieve many of the same effects as calorie restriction, though protein restriction is generally better tolerated by humans than severe calorie restriction. In other words, the subject technology can be implemented effectively without restricting calories.
[0048] Example for treatment of neurodegeneration [0049] As proof of principle for the subject technology, an experimental study using dietary protein restriction cycles was performed and resulted in reduced IGF-1 and phosphorylated tau, and improve behavioral performance, in an Alzheimer's disease (AD) mouse model. Reduced levels of growth hormone and IGF-1, which mediate some of the protective effects of caloric restriction (CR), can also extend longevity and protect against age-related diseases in rodents and humans. Four months of periodic protein restriction cycles (PRC) with supplementation of non-essential amino acids in mice already displaying significant cognitive impairment and AD-like pathology reduced circulating IGF-1 levels by 30-70% and caused an 8- fold increase in IGFBP-1. The protein cycles lasted four months and consisted of alternating weeks of a normal diet and a protein-restricted (PR) diet. The PR diet lacked nine essential amino acids (EAA) - that is, amino acids the body cannot make: isoleucine, leucine, lysine, methionine, phenyalanine, threonine, tryptophan, valine, and arginine. Both the treatment and normal diets contained about 60% carbohydrate
[0050] Whereas PRC did not affect levels of β amyloid (Αβ) when non-essential amino acids were supplemented, it decreased tau phosphorylation in the hippocampus and alleviated the age-dependent impairment in cognitive performance. These results indicate that periodic protein restriction cycles without CR can promote changes in circulating growth factors and tau phosphorylation associated with protection against age-related neuropathologies. Even better protection against neurodegeneration can occur, according to the subject technology, with restriction both of essential amino acids, such as leucine, and non-essential amino acids, such as glutamine.
[0051] One approach to treating and/or preventing any disease according to the subject technology is to restrict protein markedly for a first period, then to resume normal protein feeding during a second period. This accomplishes two goals: (1) stimulating autophagy during the first period, thereby helping clear cells of debris; and (2) preventing protein malnutrition during the second period.
[0052] In some embodiments, protein intake may be restricted for up to one day, followed by a period of differing protein intake. The subject technology, however, also includes restricting protein for longer periods, for at least two days, for example, followed by a period of normal to high protein intake. This produces the unexpected result of achieving a more profound degree of autophagy in a subject without producing protein deficiency, protein malnutrition, or protein-calorie malnutrition. This longer duration of autophagy better assists in clearing cells of abnormal proteins (e.g., oxidized, glycated, and fructated proteins) and abnormal organelles, such as mitochondria and lysosomes. This can assist in preventing and treating diseases caused or exacerbated by an accumulation of cellular debris, such as in the heart, pancreas, liver, brain, and skeletal muscles, leading to organ dysfunction.
[0053] Protein restriction and cancer
[0054] Protein restriction can be used according to the subject technology to enhance autophagy and, in some cases, induce cell death, through apoptosis or otherwise, in patients with neoplasms that either benign (e.g., meningioma) or malignant (e.g., astrocytoma). In glioma cells, the drug minocycline induces nonapoptotic cell death, which is associated with the presence of autophagic vacuoles in the cytoplasm. Minocycline induces autophagy, as confirmed by acridine orange, monodansylcadaverine (MDC) stainings of vesicle formation, and the conversion of microtubule-associated proteins light chain 3 (LC3-I) to LC3-II. Pretreatment with autophagy inhibitor 3-methyladenine (3-MA) suppresses induction of acidic vesicular organelles and the accumulation of LC3-II to the autophagosome membrane in glioma cells treated with minocycline. Despite the pretreatment of 3-MA, minocycline induces cell death via apparent activation of caspase-3. Minocycline effectively inhibits tumor growth and induces autophagy in the xenograft tumor model of C6 glioma cells. Thus, minocycline appears to kill glioma cells by inducing autophagic cell death. As a result, stimulation of autophagy by restriction of protein intake according to principles of the subject technology is a promising therapeutic intervention for malignant gliomas and other cancers.
[0055] Protein restriction in autoimmune disorders
[0056] As used herein, an "autoimmune disorder" is any disorder known or suspected by medical researchers to be related to self-targeting of a mammalian (e.g., human) immune system, such that inflammation results. Each of the following disorders is known or suspected to be autoimmune in nature and can, in certain cases, be treated, prevented, and/or have its severity or progression lessened in a person by restriction of the person's bodily intake of protein according to methods and systems of the subject technology. Accepted/Suspected as
Name of Disorder
Autoimmune
; Acute disseminated encephalomyelitis(ADEM) Accepted
; Addison's Disease
; Agammaglobulinemia
; Alopecia areata Accepted
I Amyotrophic Lateral Sclerosis
I Ankylosing Spondylitis Accepted
I Antiphospholipid syndrome Accepted
i Antisynthetase syndrome
i Atopic allergy
; Atopic dermatitis
; Autoimmune aplastic anemia
i Autoimmune cardiomyopathy Accepted
I Autoimmune enteropathy
I Autoimmune hemolytic anemia Accepted
i Autoimmune hepatitis Accepted
i Autoimmune inner ear disease Accepted
; Autoimmune lymphoproliferative syndrome Accepted
; Autoimmune peripheral neuropathy Accepted
I Autoimmune pancreatitis Accepted
I Autoimmune polyendocrine syndrome Accepted
I Autoimmune progesterone dermatitis Accepted
i Autoimmune thrombocytopenic purpura Accepted
I Autoimmune urticaria Accepted
i Autoimmune uveitis Accepted
Balo disease/Balo concentric sclerosis
I Behcet's disease
I Berger's disease
I Bickerstaff s encephalitis
i Blau syndrome Bullous pemphigoid
i Cancer
i Castleman's disease
i Celiac disease Accepted i Chagas disease Suspected i Chronic inflammatory demyelinating polyneuropathy
i Chronic recurrent multifocal osteomyelitis
i Chronic obstructive pulmonary disease i Suspected i Churg-Strauss syndrome
i Cicatricial pemphigoid
i Cogan syndrome
1 Cold agglutinin disease i Accepted i Complement component 2 deficiency
i Contact dermatitis
i Cranial arteritis
i CREST syndrome
i Crohns Disease (one of two types of idiopathic
! inflammatory bowel disease "IBD")
i Cushing's Syndrome
i Cutaneous leukocytoclastic angiitis
i Dego's disease
i Dercum's disease i Suspected i Dermatitis herpetiformis
i Dermatomyositis i Accepted i Diabetes mellitus type 1 1 Accepted i Diffuse cutaneous systemic sclerosis
i Dressler's syndrome
1 Drug-induced lupus
i Discoid lupus erythematosus
i Eczema
i Endometriosis i Suspected i Enthesitis-related arthritis
i Eosinophilic fasciitis Accepted i Eosinophilic gastroenteritis
i Epidermolysis bullosa acquisita
i Erythema nodosum
i Erthroblastosis fetalis
i Essential mixed cryoglobulinemia
i Evan's syndrome
i Fibrodysplasia ossificans progressiva
i Fibrosing aveolitis akaldiopathic pulmonary fibrosis
i Gastritis
i Gastrointestinal pemphigoid Accepted i Giant cell arteritis
1 Glomerulonephritis Sometimes i Goodpasture's syndrome Accepted i Graves' disease Accepted i Guillain-Barre syndrome (GBS) Accepted i Hashimoto's encephalopathy Accepted i Hashimoto's thyroiditis Accepted i Henoch-Schonlein purpura
1 Herpes gestationis aka Gestational Pemphigoid
i Hidradenitis suppurativa Suspected i Hypogammaglobulinemia
i Idiopathic Inflammatory Demyelinating Diseases
i Idiopathic pulmonary fibrosis
i Idiopathic thrombocytopenic purpura (SeeAutoimmune
Accepted i thrombocytopenic purpura)
i IgA nephropathy
i Inclusion body myositis
1 Chronic inflammatory demyelinating polyneuropathy
i Interstitial cystitis Suspected i Juvenile idiopathic arthritis aka Juvenile rheumatoid
1 arthritis
i Kawasaki's Disease Suspected i Lambert-Eaton myasthenic syndrome i Leukocytoclastic vasculitis
i Lichen planus
i Lichen sclerosus
i Linear IgA disease (LAD)
i Lou Gehrig's disease (Also Amyotrophic lateral i sclerosis)
i Lupoid hepatitis aka Autoimmune hepatitis
1 Lupus erythematosus Accepted
! Majeed syndrome
i Meniere's disease
i Microscopic polyangiitis
i Miller-Fisher syndrome see Guillain-Barre Syndrome Accepted i Mixed Connective Tissue Disease Accepted i Morphea Suspected
1 Mucha-Habermann disease aka Pityriasis lichenoides et i varioliformis acuta i Multiple sclerosis Suspected
1 Myasthenia gravis Accepted i Myositis
i Narcolepsy Suspected i Neuromyelitis optica (Also Devic's Disease)
i Neuromyotonia Suspected i Occular cicatricial pemphigoid
i Opsoclonus myoclonus syndrome Suspected
1 Ord's thyroiditis
i Palindromic rheumatism
i PANDAS (pediatric autoimmune neuropsychiatric
Suspected disorders associated with streptococcus)
i Paraneoplastic cerebellar degeneration
i Paroxysmal nocturnal hemoglobinuria (PNH) Sometimes i Parry Romberg syndrome
i Parsonnage-Turner syndrome
i Pars planitis Pemphigus vulgaris Accepted i Pernicious anaemia 1 Accepted i Perivenous encephalomyelitis
: POEMS syndrome
i Polyarteritis nodosa
i Polymyalgia rheumatica
i Polymyositis i Accepted i Primary biliary cirrhosis : Accepted Primary sclerosing cholangitis
i Progressive inflammatory neuropathy ; Suspected i Psoriasis Accepted i Psoriatic arthritis i Accepted i Pyoderma gangrenosum
i Pure red cell aplasia
i Rasmussen's encephalitis
i Raynaud phenomenon 1 Suspected i Relapsing polychondritis Accepted i Reiter's syndrome
i Restless leg syndrome i Suspected
1 Retroperitoneal fibrosis
i Rheumatoid arthritis I Accepted i Rheumatic fever
i Sarcoidosis 1 Suspected i Schizophrenia Suspected
: Schmidt syndrome another form of APS
i Schnitzler syndrome
i Scleritis
i Scleroderma i Suspected i Serum Sickness
i Sjogren's syndrome ; Accepted
Spondyloarthropathy
Still's disease see Juvenile Rheumatoid Arthritis i Stiff person syndrome i Suspected
i Subacute bacterial endocarditis (SBE)
i Susac's syndrome
i Sweet's syndrome
i Sydenham chorea (see PANDAS)
i Sympathetic ophthalmia
i Systemic lupus erythematosis see Lupus erythematosis
i Takayasu's arteritis
i Temporal arteritis (also known as "giant cell arteritis") 1 Accepted
i Thrombocytopenia
i Tolosa-Hunt syndrome
1 Transverse myelitis i Accepted
i Ulcerative colitis (one of two types of idiopathic : Δ
i inflammatory bowel disease "IBD")
1 Undifferentiated connective tissue diseasedifferent from
: Accepted
i Mixed connective tissue disease
1 Undifferentiated spondyloarthropathy
i Urticarial vasculitis
i Vasculitis i Accepted
i Vitiligo 1 Suspected
i Wegener's granulomatosis Accepted
[0057] According to embodiments of the subject technology, by restricting protein intake in persons who have or are at risk for autoimmune disorders, one can decrease cellular damage, decrease the susceptibility of cells to damage, and, at least by increasing autophagy, increase cleanup of the damage in some cases.
[0058] Protein restriction in sequelae of obesity, hypertension, insulin resistance, and metabolic syndrome
[0059] In both genetic and dietary models of obesity, one can observe a marked downregulation of autophagy, particularly in Atg7 expression levels in liver. Suppression of Atg7 both in vitro and in vivo results in defective insulin signaling and elevated endoplasmic reticulum (ER) stress. In contrast, restoration of Atg7 expression in liver results in dampened ER stress, enhanced hepatic insulin action, and systemic glucose tolerance in obese mice. Beneficial Atg7 restoration in obese mice can be prevented by blocking a downstream autophagy mediator, Atg5, supporting the concept of AtgVs dependence on autophagy for regulating insulin action. Thus, autophagy is an important regulator of organelle function and insulin signaling, and loss of autophagy contributes strongly to the defective insulin action of obesity, which in turn leads to many known sequelae and is associated with, for example, hypertension, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, certain cancers, cholelithiasis, depression, coronary artery disease, peripheral vascular disease, type 2 diabetes, Alzheimer's disease, and other dementia syndromes.
[0060] Protein restriction in diabetes mellitus
[0061] Type 2 diabetes mellitus is characterized by insulin resistance and failure of pancreatic beta cells producing insulin. Mitochondrial dysfunction plays a role in both processes of diabetes. Autophagy, which can be upregulated by restriction of dietary energy and/or protein, maintains cellular homeostasis through degradation and recycling of organelles such as mitochondria. As dysfunctional mitochondria are the main organelles removed by autophagy, one can observe the role of autophagy in diabetes using mice with beta cell-specific deletion of, for example, the Atg7 gene. Atg7-mutant mice show reduction in beta cell mass and pancreatic insulin content. Electron microscopy shows swollen mitochondria and other ultrastructural changes in autophagy-deficient beta cells. Insulin secretory function ex vivo is also impaired. As a result, Atg7-mutant mice show hypoinsulinemia and hyperglycemia. Autophagy appears necessary to maintain structure, mass, and function of beta cells. Besides its effect on beta cells, autophagy affects insulin sensitivity because mitochondrial dysfunction is implicated in insulin resistance and autophagy is involved in the maintenance of organelles, including mitochondria. Furthermore, since aging is associated with impaired glucose tolerance, decline of autophagic activity appears to be involved in age-associated reduction of glucose tolerance.
[0062] Protein restriction in infection
[0063] Autophagy acts an immune mechanism. One of the model systems showing how autophagy and more traditional immunity systems cooperate in defense against intracellular pathogens is macrophage infection with Mycobacterium tuberculosis. M. tuberculosis is a significant human pathogen that latently infects billions of people and causes active disease in millions of patients worldwide. The ability of the tubercle bacillus to persist in human populations rests upon its macrophage parasitism. Autophagy can act as a cell-autonomous innate immunity mechanism capable of eliminating intracellular bacteria, e.g., M. tuberculosis. Embodiments of the subject technology recognize that: (1) autophagy functions as an innate defense mechanism against intracellular microbes; (2) autophagy is under the control of pattern recognition receptors (PRR) such as Toll-like receptors (TLR), and it acts as an immunological output effector of PRR and TLR signaling; (3) autophagy is one of the effector functions associated with the immunity-regulated GTPases, which are molecules involved in cell- autonomous defense; (4) autophagy is an immune effector of Thl/Th2 T cell response polarization— autophagy is activated by Thl cytokines (acting in defense against intracellular pathogens) and is inhibited by Th2 cytokines (making cells accessible to intracellular pathogens). As an ancient innate immunity defense, autophagy became integrated over the course of evolution with other immune mechanisms of increasing complexity.
[0064] Protein restriction and macular degeneration
[0065] Age-related macular degeneration (AMD) is the major cause of blindness in the elderly, over 1.75 million people having reduced vision due to AMD in the United States. AMD is broadly divided into two forms, dry and wet, that account for about 85% and 15% of cases, respectively. An early sign of AMD is the appearance of drusen, which are extracellular deposits that accumulate on Bruch' s membrane, and are thought to derive from the overlying retinal pigment epithelium (RPE). Scientists have proposed that increased autophagy and the release of intracellular proteins via exosomes by the aged RPE may contribute to the formation of drusen. Furthermore, a decline in autophagic efficiency in the RPE is associated with the later pathological stages of AMD and cellular dysfunction.
[0066] Protein restriction in glaucoma and retinal ischemia
[0067] Primary open angle glaucoma is an optic neuropathy characterized by the elevation of intraocular pressure, which causes retinal ischemia and neuronal death. Following ischemia/reperfusion (I/R) lesioning in rats, inhibition of autophagy by 3-methyladenine partially prevents death of neurons and reduces apoptotic markers, 24 h post-lesion. The number of neurons in the GCL decreases significantly following I/R; this decrease is partially prevented by 3-methyladenine, which potently inhibits maturation of autophagosomes. Treatment also prevents the increase in glial fibrillary acid protein immunoreactivity elicited by I/R. Therefore, stimulating autophagy provides treatment for glaucoma and retinal ischemia.
[0068] Protein restriction in osteoporosis
[0069] Osteoporosis, osteopenia, and other disorders of bone density and/or mineralization can, in certain cases, be treated, prevented, and/or have its severity or progression lessened in a person by episodic restriction of the person' s bodily intake of protein according to methods and systems of the subject technology.
[0070] Protein restriction in chronic kidney disease
[0071] Chronic kidney disease can, in certain cases, be treated, prevented, and/or have its severity or progression lessened in a person by episodic restriction of the person's bodily intake of protein according to methods and systems of the subject technology.
[0072] Protein restriction and male pattern baldness
[0073] Male pattern baldness, or alopecia androgenica, is marked typically by higher levels of 5-alpha-reductase, lower levels of total testosterone, higher levels of unbound/free testosterone, and higher levels of total free androgens including DHT. 5-alpha-reductase is responsible for converting free testosterone into DHT. The enzymes are present predominantly in the scalp and prostate. Levels of 5-alpha-reductase are one factor in determining levels of DHT in the scalp. Drugs which interfere with 5-alpha-reductase (such as finasteride, which inhibits the predominant type 2 isoform) have been approved by the FDA as treatments for hair loss.
[0074] Sex hormone-binding globulin (SHBG), which is responsible for binding testosterone and preventing its bioavailability and conversion to DHT, is typically lower in individuals with high DHT. SHBG is downregulated by insulin.
[0075] Increased levels of Insulin Growth Factor- 1 (IGF-1) have been correlated to vertex balding, and IGF-1 may be lowered by protein restriction. High insulin levels seem a possible link between metabolic syndrome and baldness. Low levels of SHBG in men and nonpregnant women are also correlated with glucose intolerance and diabetes risk, though this correlation disappears during pregnancy.
[0076] By increasing autophagy by protein restriction, destruction of hair follicles and consequent hair loss can in some cases be delayed or possibly avoided. [0077] Cumulative uptake of glutamine into the cells results in increases in cellular hydration, activating osmosignaling pathways involving mitogen- activated protein kinases (MAPK). Glutamine- and hypoosmolarity-induced cell swelling activates extracellular signal- regulated kinases (ERK) and ρβδ^^. Glutamine- induced ρβδ^^ activation mediates inhibition of autophagic proteolysis at the level of autophagosome formation. Moreover, glutamine is transported into cells via the SLC1A5 glutamine transporter and is subsequently used to import leucine via the SLC7A5-SLC3A2 complex. Intracellular leucine activates mTORCl Rag GTPases or a second pathway. Basal autophagy is maintained under these conditions by the activity of Beclin-1, which is inhibited by anti-apoptotic Bcl-2 and Bel -XL. Bcl-2 and Bcl-XL also function to maintain viability by antagonizing Bax/Bak-dependent mitochondrial apoptosis. The ability of essential amino acids (EAA), e.g., leucine, to enter cells and activate mTORCl signaling apparently depends on their exchange for glutamine. Under conditions of glutamine depletion, the resulting decline in leucine import reduces amino acid- dependent activation of mTORCl. L-glutamine flux regulates mTOR, translation and autophagy to coordinate cell growth and proliferation. Also, arginine deprivation also activates autophagy, e.g., in T lymphocytes and other cell types. Restriction of glutamine and/or leucine and/or arginine intake, e.g., in the diet, can therefore enhance or activate autophagy in accordance with principles of the subject technology..
[0078] Furthermore, the decrease in mitochondrial reactive oxygen species (mitROS) generation and oxidative damage to mitochondrial DNA (mtDNA) that occurs during life- extending dietary restriction also occurs during protein or methionine restriction, whereas it apparently does not take place during carbohydrate or lipid restriction. Restriction of methionine intake is therefore also beneficial in conjunction with principles of the subject technology.
[0079] Polyunsaturated fatty acids
[0080] Enrichment of omega-6 (co-6) polyunsaturated fatty acids (PUFAs) promotes starvation resistance and extends Caenorhabditis elegans life span. Upon fasting, C. elegans induces expression of a lipase, leading to an enrichment of co-6 PUFAs. Supplementing C. elegans culture media with these co-6 PUFAs increases their resistance to starvation and extends their life span in conditions of food abundance. Supplementation of C. elegans or human epithelial cells with these co-6 PUFAs activates autophagy, a cell recycling mechanism that promotes starvation survival and slows aging. Inactivation of C. elegans autophagy components reverses the increase in life span conferred by supplementing the C. elegans diet with these fasting-enriched co-6 PUFAs. Dietary supplementation with co-3/6 PUFAs (fish oils) is beneficial due, at least in part, to activation of autophagy.
[0081] The omega-3 long chain polyunsaturated fatty acids docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) elicit anti-proliferative effects in cancer cell lines and in animal models. Dietary DHA and EPA can be converted to their ethanolamide derivatives, docosahexaenoyl ethanolamine (DHEA), and eicosapentaenoyl ethanolamine (EPEA), respectively. DHEA and EPEA reduce cell viability in MCF-7 breast cancer cells whereas they do not elicit effects in MCF-IOA non-tumorigenic breast epithelial cells. DHA and EPA are ligands of Peroxisome Proliferator-Activated Receptor gamma (PPARy). In MCF-7 cells, both compounds enhanced PPARy expression, stimulated a PPAR response element-dependent transcription as confirmed by the increased expression of its target gene PTEN, resulting in the inhibition of AKT-mTOR pathways. DHEA and EPEA treatment induce phosphorylation of Bcl- 2, promoting its dissociation from beclin-1 which results in autophagy induction. The two omega-3 ethanolamides exert anti-proliferative effects by inducing autophagy in breast cancer cells highlighting their potential use as breast cancer preventive and/or therapeutic agents. Supplementation of omega-3 and/or omega-6 fatty acids is effective for amelioration of diseases according to principles of the subject disclosure.
[0082] The foregoing description is provided to enable a person skilled in the art to practice the various configurations described herein. While the subject technology has been particularly described with reference to the various figures and configurations, it should be understood that these are for illustration purposes only and should not be taken as limiting the scope of the subject technology.
[0083] There may be many other ways to implement the subject technology. Various functions and elements described herein may be partitioned differently from those shown without departing from the scope of the subject technology. Various modifications to these configurations will be readily apparent to those skilled in the art, and generic principles defined herein may be applied to other configurations. Thus, many changes and modifications may be made to the subject technology, by one having ordinary skill in the art, without departing from the scope of the subject technology.
[0084] As used herein, "a period of at least" a particular time (e.g., "a period of at least one day") refers to time period having of a duration of at least as long as that time (e.g., a period lasting one day or more in duration).
[0085] As used herein, a phrase such as "instructing that the material be administered to X" (e.g., a person) can refer either to self-administration by X, or to administration to X by another person or agent, such as a health care worker or a machine, such as a robot.
[0086] As used herein, the terms "all protein" and "all of any protein" have at least their ordinary meaning and are further defined to include all proteins, peptides, polypeptides, and amino acids, free or otherwise, in a particular material, food, meal, other circumstance, or time period of consumption, ingestion, or administration.
[0087] As used herein, "meal" is a broad term that encompasses its ordinary meaning and can refer to a food and/or drink (or beverage) portion of any size, such as a snack or food "treat," whether frozen, chilled, hot, cookable, microwaveable, reheatable, or raw. Such a meal may be ingested enterally, such as orally or by gastrostomy.
[0088] Any of the methods or systems of periodic or episodic protein restriction described herein may be used, as will be evident to one skilled in the art, for any of the diseases and conditions listed in this description of the subject technology. The amounts and timing of macronutrient administration may be altered or titrated according to patient response.
[0089] It is understood that the specific order or hierarchy of steps in the processes disclosed is an illustration of exemplary approaches. Based upon design preferences, it is understood that the specific order or hierarchy of steps in the processes may be rearranged. Some of the steps may be performed simultaneously. The accompanying method claims present elements of the various steps in a sample order, and are not meant to be limited to the specific order or hierarchy presented.
[0090] As used herein, the phrase "at least one of preceding a series of items, with the term "and" or "or" to separate any of the items, modifies the list as a whole, rather than each member of the list (i.e., each item). The phrase "at least one of can include, but does not require, selection of at least one of each item in the series. Rather, the phrase allows a meaning that includes at least one of any one of the items, and/or at least one of any combination of the items, and/or at least one of each of the items. By way of example, the phrase "at least one of A, B, and C" includes at least one of only A, of only B, of only C, of any combination of A, B, and C; and/or of each of A, B, and C.
[0091] Terms such as "top," "bottom," "front," "rear" and the like as used in this disclosure should be understood as referring to an arbitrary frame of reference, rather than to the ordinary gravitational frame of reference. Thus, a top surface, a bottom surface, a front surface, and a rear surface may extend upwardly, downwardly, diagonally, or horizontally in a gravitational frame of reference.
[0092] Furthermore, to the extent that the term "include," "have," or the like is used in the description or the claims, such term is intended to be inclusive in a manner similar to the term "comprise" as "comprise" is interpreted when employed as a transitional word in a claim.
[0093] The word "exemplary" is used herein to mean "serving as an example, instance, or illustration." Any embodiment described herein as "exemplary" is not necessarily to be construed as preferred or advantageous over other embodiments.
[0094] A reference to an element in the singular is not intended to mean "one and only one" unless specifically stated, but rather "one or more." Pronouns in the masculine (e.g., his) include the feminine and neuter gender (e.g., her and its) and vice versa. The term "some" refers to one or more. Underlined and/or italicized headings and subheadings are used for convenience only, do not limit the subject technology, and are not referred to in connection with the interpretation of the description of the subject technology. All structural and functional equivalents to the elements of the various configurations described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and intended to be encompassed by the subject technology. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the above description.
[0095] While certain aspects and embodiments of the invention have been described, these have been presented by way of example only, and are not intended to limit the scope of the invention. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms without departing from the spirit thereof. The accompanying claims and their equivalents are intended to cover such forms or modifications as would fall within the scope and spirit of the invention.

Claims

WHAT IS CLAIMED IS:
1. Nutrient material for use in preventing or treating neurodegeneration, by administration to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
wherein all of any protein in a first portion of the material constitutes no more than 5 percent of a caloric content of the material;
wherein all of any protein in a second portion of the material constitutes at least 10 percent of a caloric content of the material; and
wherein the use is such that:
(a) the first portion is administered to the person such that person's bodily intake of all protein is restricted to less than 30 grams per day during a lower-protein time period of at least 48 hours;
(b) nutrition is administered to the person such that the person's bodily intake of carbohydrate constitutes at least 40 percent of the person's bodily intake of energy during the lower-protein period; and
(c) the second portion is administered to the person during a higher-protein time period that is after the lower-protein period and is at least 24 hours and no more than 14 days, such that the person receives a higher daily bodily intake of protein than the person received during the lower-protein period.
2. The nutrient material of claim 1, wherein the use is such that the person's caloric intake is not restricted during at least one of the lower-protein period or the higher-protein period.
3. The nutrient material of claim 1, further comprising at least one of an omega-3 or an omega-6 fatty acid.
4. The nutrient material of claim 1, wherein the use is such that the person's bodily intake of carbohydrate constitutes at least 60 percent of the person's bodily intake of calories during the lower-protein period.
5. The nutrient material of claim 1, wherein the use is such that the person's bodily intake of carbohydrate constitutes at least 80 percent of the person's bodily intake of calories during the lower-protein period.
6. The nutrient material of claim 1 , wherein the use is such that the person's bodily intake of carbohydrate is at least 100 grams per day during the lower-protein period.
7. The nutrient material of claim 1, wherein carbohydrate in the material constitutes at least 50 percent of the caloric content of the material.
8. The nutrient material of claim 1, wherein carbohydrate in the material constitutes at least 90 percent of the caloric content of the material.
9. The nutrient material of claim 1, wherein the use is such that the average daily bodily intake of all protein during the higher-protein period that is at least 40 grams.
10. The nutrient material of claim 1 , wherein the use is such that at least some of the carbohydrate instructed to be administered to the person during the lower-protein period.
11. The nutrient material of claim 1 , comprising individually packaged servings of the material, wherein all of any protein in the material constitutes no more than 15 grams per serving.
12. The nutrient material of claim 1, wherein the material comprises carbohydrate, and wherein the use is such that such that the person's bodily intake of carbohydrate in the material is at least 40 grams per day during the lower-protein period.
13. The nutrient material of claim 1, wherein the use is such that the person's bodily intake of all protein is restricted to less than 10 grams per day during the lower-protein period.
14. The nutrient material of claim 1, wherein the use is such that the person's bodily intake of all protein is restricted to less than 0.3 g per kilogram of the person's bodyweight per day during the lower-protein period.
15. The nutrient material of claim 1, wherein the use is such that, during the higher- protein period, the person receives a bodily intake of all protein of at least 50 grams.
16. The nutrient material of claim 1, wherein the use is such that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.6 g per kilogram of the person's body weight.
17. The nutrient material of claim 1, wherein the use is such that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.8 g per kilogram of the person's body weight.
18. The nutrient material of claim 1, wherein the lower-protein period is at least 3 days.
19. The nutrient material of claim 1, wherein the lower-protein period is at least 4 days.
20. The nutrient material of claim 1, wherein the higher-protein period is no more than 5 days.
21. The nutrient material of claim 1, wherein the higher-protein period is no more than 3 days.
22. The nutrient material of claim 1 , wherein the use is such that, during the higher- protein period, the person receives, within a period of 4 hours or less, at least 90 percent of a bodily intake of all protein received in a day.
23. The nutrient material of claim 1, wherein leucine and glutamine are substantially absent in the nutrient material.
24. The nutrient material of claim 60, wherein arginine is substantially absent in the nutrient material.
25. The nutrient material of claim 60, wherein methionine is substantially absent in the nutrient material.
26. The nutrient material of claim 1 , wherein methionine is substantially absent in the nutrient material.
27. The nutrient material of claim 1, wherein a concentration of leucine and a concentration of glutamine in the nutrient material are each lower than are concentrations of other amino acids in the nutrient material.
28. The nutrient material of claim 1, wherein leucine and glutamine are substantially absent in the nutrient material, and another amino acid is present in the nutrient material.
29. The nutrient material of claim 67, wherein methionine is substantially absent in the nutrient material.
30. The nutrient material of claim 29, wherein a concentration of methionine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
31. The nutrient material of claim 29, wherein a concentration of arginine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
32. The nutrient material of claim 1, wherein a concentration of leucine and a concentration of glutamine in the nutrient material are each lower than are concentrations of other amino acids in the nutrient material.
33. The nutrient material of claim 1, wherein a concentration of leucine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
34. The nutrient material of claim 1, wherein a concentration of glutamine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
35. The nutrient material of claim 29, wherein a concentration of methionine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
36. The nutrient material of claim 29, wherein a concentration of arginine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
37. The nutrient material of claim 1, wherein the nutrient material is more restricted in leucine and glutamine content than in the content of other amino acids.
38. A method for providing nutrients to a person to slow or prevent neurodegeneration, comprising:
providing nutrient material administrable to at least one of a person's gastrointestinal tract or intravascular space and comprising at least one of lipid or carbohydrate;
wherein all of any protein in the material constitutes no more than 5 percent of a caloric content of the material;
instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 30 grams per day during a lower- protein time period of at least 48 hours;
instructing that nutrition be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 40 percent of the person's bodily intake of energy during the lower-protein period; and
instructing that, during a higher-protein time period that is after the lower-protein period and is at least 24 hours and no more than 30 days, the person receives a higher daily bodily intake of protein than the person received during the lower-protein period.
39. The method of claim 38, further comprising not instructing that the person's caloric intake be restricted during at least one of the lower-protein period or the higher-protein period.
40. The method of claim 38, wherein the nutrient material comprises at least one of an omega-3 or an omega-6 fatty acid.
41. The method of claim 38, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 60 percent of the person's bodily intake of calories during the lower-protein period.
42. The method of claim 38, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate constitutes at least 80 percent of the person's bodily intake of calories during the lower-protein period.
43. The method of claim 38, further comprising instructing that carbohydrate be administered to the person such that the person's bodily intake of carbohydrate is at least 100 grams per day during the lower-protein period.
44. The method of claim 38, wherein carbohydrate in the material constitutes at least 50 percent of the caloric content of the material.
45. The method of claim 38, wherein carbohydrate in the material constitutes at least 90 percent of the caloric content of the material.
46. The method of claim 38, further comprising instructing that the person receives an average daily bodily intake of all protein during the higher-protein period that is at least 40 grams.
47. The method of claim 38, wherein the material comprises at least some of the carbohydrate instructed to be administered to the person during the lower-protein period.
48. The method of claim 38, wherein the providing the material comprises providing individually packaged servings of the material, and the all of any protein in the material constitutes no more than 15 grams per serving.
49. The method of claim 38, wherein the material comprises carbohydrate, and further comprising instructing that the material be administered to the person such that the person's bodily intake of carbohydrate in the material is at least 40 grams per day during the lower-protein period.
50. The method of claim 38, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 10 grams per day during the lower-protein period.
51. The method of claim 38, further comprising instructing that the material be administered to the person such that the person's bodily intake of all protein is restricted to less than 0.3 g per kilogram of the person's bodyweight per day during the lower-protein period.
52. The method of claim 38, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 50 grams.
53. The method of claim 38, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.6 g per kilogram of the person's body weight.
54. The method of claim 38, further comprising instructing that, during the higher- protein period, the person receives a bodily intake of all protein of at least 0.8 g per kilogram of the person's body weight.
55. The method of claim 38, wherein the lower-protein period is at least 3 days.
56. The method of claim 38, wherein the lower-protein period is at least 4 days.
57. The method of claim 38, wherein the higher-protein period is no more than 5 days.
58. The method of claim 38, wherein the higher-protein period is no more than 3 days.
59. The method of claim 38, further comprising instructing that, during the higher- protein period, the person receives, within a period of 4 hours or less, at least 90 percent of a bodily intake of all protein received in a day.
60. The method of claim 38, wherein leucine and glutamine are substantially absent in the nutrient material.
61. The method of claim 60, wherein arginine is substantially absent in the nutrient material.
62. The method of claim 60, wherein methionine is substantially absent in the nutrient material.
63. The method of claim 38, wherein methionine is substantially absent in the nutrient material.
64. The method of claim 38, wherein a concentration of leucine and a concentration of glutamine in the nutrient material are each lower than are concentrations of other amino acids in the nutrient material.
65. The method of claim 38, wherein leucine and glutamine are substantially absent in the nutrient material, and another amino acid is present in the nutrient material.
66. The method of claim 67, wherein methionine is substantially absent in the nutrient material.
67. The method of claim 60, wherein a concentration of methionine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
68. The method of claim 60, wherein a concentration of arginine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
69. The method of claim 38, wherein a concentration of leucine and a concentration of glutamine in the nutrient material are each lower than are concentrations of other amino acids in the nutrient material.
70. The method of claim 38, wherein a concentration of leucine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
71. The method of claim 38, wherein a concentration of glutamine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
72. The method of claim 60, wherein a concentration of methionine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
73. The method of claim 60, wherein a concentration of arginine in the nutrient material is lower than are concentrations of other amino acids in the nutrient material.
74. The method of claim 38, wherein the nutrient material is more restricted in leucine and glutamine content than in the content of other amino acids.
PCT/US2013/031061 2012-04-09 2013-03-13 Protein restriction for disease prevention and treatment WO2013154733A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261621959P 2012-04-09 2012-04-09
US61/621,959 2012-04-09
US201261671591P 2012-07-13 2012-07-13
US61/671,591 2012-07-13
US201261679782P 2012-08-06 2012-08-06
US61/679,782 2012-08-06
US13/604,535 2012-09-05
US13/604,535 US9578892B2 (en) 2011-09-13 2012-09-05 Protein restriction for disease prevention and treatment

Publications (1)

Publication Number Publication Date
WO2013154733A1 true WO2013154733A1 (en) 2013-10-17

Family

ID=49328022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/031061 WO2013154733A1 (en) 2012-04-09 2013-03-13 Protein restriction for disease prevention and treatment

Country Status (1)

Country Link
WO (1) WO2013154733A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548483B2 (en) * 2000-05-08 2003-04-15 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
WO2006124675A2 (en) * 2005-05-13 2006-11-23 Hill's Pet Nutrition, Inc. Dry food compositions having enhanced palatability
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
WO2009072884A1 (en) * 2007-12-05 2009-06-11 N.V. Nutricia Liquid enteral nutritional composition with a low specific protein volume

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548483B2 (en) * 2000-05-08 2003-04-15 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
WO2006124675A2 (en) * 2005-05-13 2006-11-23 Hill's Pet Nutrition, Inc. Dry food compositions having enhanced palatability
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
WO2009072884A1 (en) * 2007-12-05 2009-06-11 N.V. Nutricia Liquid enteral nutritional composition with a low specific protein volume

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CHEN J. ET AL.: "Glutamine acts as a neuroprotectant against DNA damage, beta- amyloid and H202-induced stress", PLOS ONE, vol. 7, no. 3, 2012, pages E33177, Retrieved from the Internet <URL:http://ncbi.nlm.nih.gov/pmc/articles/PMC3297635/?reporrabstract> [retrieved on 20130521] *
COLLINS S. ET AL.: "Dietary treatment of severe malnutrition in adults", AM J CLIN NUTR., vol. 68, no. 1, July 1998 (1998-07-01), pages 193 - 199 *
DAS UN.: "Folic acid says NO to vascular diseases", NUTRITION, vol. 19, no. 7- 8, July 2003 (2003-07-01), pages 686 - 692 *
DATABASE PUBMED accession no. 665114 *
MACHADO J. ET AL.: "Nutritional status in Alzheimer's disease».", REV. ASSOC.MED. BRAS., vol. 55, no. 2, 2009, pages 188 - 91 *
MELNIK B.C.: "Leucine signaling in the pathogenesis of type 2 diabetes and obesity.", WORLD J. DIABETES., vol. 3, no. 3, 15 March 2012 (2012-03-15), pages 38 - 53 *
N.V. VERBITSKOY ET AL.: "AGROPROMIZDAT", DIETICHESKAYA KUKHNYA. POD RED., 1991, MOSKVA, pages 14 *
PEDRINI S. ET AL.: "Dietary composition modulates brain mass and solubilizable Abeta levels in mouse model of aggressive Alzheimer's amyloid pathology».", MOL. NEURODEGENER., vol. 4, no. 40, 21 October 2009 (2009-10-21), pages 1 - 10 *
WILLETT B., LOW PROTEIN & NUTRITION, 14 June 2011 (2011-06-14), pages 1, Retrieved from the Internet <URL:http://www.livestrong.com/article/295669-low-protein-nutrition> [retrieved on 20130520] *
YOUNG KW. ET AL.: "A randomized, crossover trial of high-carbohydrate foods in nursing home resident with Alzheimer's disease: associations among intervention response, body mass index, and behavioral and cognitive function", J GERONTOL A BIOL SCI MED SCI., vol. 60, no. 8, August 2005 (2005-08-01), pages 1039 - 1045 *
ZHUO JM ET AL.: "Normalization ofhyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimerdisease", FASEB J., vol. 24, no. 10, October 2010 (2010-10-01), pages 3895 - 902 *

Similar Documents

Publication Publication Date Title
JP2021058191A (en) Methods, compositions and devices for supplying dietary fatty acid needs
RU2014122168A (en) IMPROVEMENT OF MEMORY IN PATIENTS WITH AN ESTIMATION OF 24-26 SCORES BY THE SHORT SCALE OF THE ASSESSMENT OF THE MENTAL STATUS
JP2012211147A (en) Use of fatty acid composition containing at least either one or combination of epa and dha
US10039732B2 (en) Nutritional composition for improving brain function in phenylketonuria
WO2014043368A1 (en) Methods for increasing brain functionality using 2-fucosyl-lactose
Savasky et al. Nutritional and pharmacological effects on oxidative stress in soft tissue and bone remodeling
US20180103674A1 (en) Protein Restriction for Diabetes
US9345727B2 (en) Nutritional compositions containing a peptide component and uses thereof
WO2013154733A1 (en) Protein restriction for disease prevention and treatment
AU2017417888B9 (en) Composition for improving efficacy of L-DOPA treatment
US10632093B2 (en) Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
WO2010017403A2 (en) Therapeutic compositions, devices and methods for observing treated tissues
Griffiths Glutamine in the critically ill patient: can it affect mortality?
US20170296499A1 (en) Combinational compositions and methods of use thereof
EP3866615B1 (en) Dietary supplement for treating dysbiosis
MX2014007936A (en) Use of reduced calorie infant formula containing nucleotides and/or carotenoids for reducing adverse health effects later in life.
Hernández et al. Role of nutrition in Inflammatory Bowel Disease (IBD): new therapeutic approaches and recent outcomes
Fukatsu et al. Fish oil infusion reverses 5-fluorouracil-induced impairments in mucosal immunity in mice
EP3442517A1 (en) Combinational compositions and methods of use thereof
Xiang Research progress on the effects of ketogenic diet on central nervous system diseases
van Esch et al. Immunoglobulin free light chains play a possible role in tolerance induction to whey proteins
Orellana et al. 14 Impact of Infection–Nutrient Interactions in Infants, Children, and Adolescents
JP2006254885A (en) Food and drink for amelioration and prophylaxis of pollinosis
Vavricka et al. Intestinal absorption and vitamin levels: Is there need for a new focus?
Harapko et al. Uzhhorod National University, Uzhhorod 1Danylo Halytsky Lviv National Medical University, Lviv PECULIARITIES OF THE EFFECT OF A HIGH-CALORIUM DIET ON THE STRUCTURE OF THE SPLEEN ON THE CORRECTION WITH ORLISTAT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13775660

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13775660

Country of ref document: EP

Kind code of ref document: A1